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Peptides and proteins are vital components of cells and are
crucial for the survival and functioning of cells. They are also im-
portant molecules in synthetic, biomedical, pharmaceutical and
materials chemistry.1 An understanding of protein structure and
function is key to both the development and sustainability of hu-
mankind.2 Unveiling of the structureefunction relationships of
peptides and proteins is a key process in the discovery of new
therapeutics. The maximum harvesting of proteins as biomolecules
enforces a deep knowledge about their post-translational modiﬁ-
cations, and the information on how they affect intrinsic biological
functions, stability, localization and in vivo 3D structural parame-
ters.3 An understanding of these phenomena is facilitated by the
availability of a facile method of synthesis, which yields proteins of
speciﬁc sequence in affordable quantities. At present, however, the
design of such an adventure at the level of proteome is imaginary
due to the mammoth size of the molecules and practical limitations
in the present synthetic protocols.
Emil Fischer’s disclosure of the synthesis of the ﬁrst synthetic
peptide Gly-Gly (by the acidic hydrolysis of the diketopiperazine of
glycine) in 1901 paved the avenue for the era of peptide science in
the biological world.4 Thereafter, the discovery of new protecting
groups made the synthesis of a variety of peptide hormones pos-
sible,5 albeit small in size (8e20 amino acid residues). du Vigneaud,
in 1953, synthesized an octapeptide hormone, oxytocin.6 With thePeptide-1 X
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Scheme 1. An outline of the general approach for chemical ligation of peptides.evolution of the methodology and developments in the chemistry
of both protection as well as coupling strategies including the
availability of sophisticated instruments (such as RP-HPLC, MPLC
and modern HPLC techniques combined with a wide range of mass
spectrometers), more and more polypeptides were made.7
A breakthrough with respect to the duration of synthesis and
length of the peptides was achieved with the discovery of solid-
phase peptide synthesis (SPPS) by Merriﬁeld in 1963.8 In due
course, the advancements and automation in the technique of SPPS
led to a revolution in the art of peptide syntheses.9 Such prodigious
advancements enabled the preparation of moderate length pep-
tides such as insulin (51 amino acids), ribonuclease A (124 amino
acids) and lysozyme (129 amino acids) successfully.10 However, the
range of achievable lengths of peptides with high chemical ho-
mogeneity (to the levels detectable by HPLC) lies around 55e60
residues. In other words, the application of SPPS to large poly-
peptide synthesis did not meet with overwhelming success. The
limitation of SPPS11e13 is that, when a peptide is assembled, thefollowing problems are encountered: (a) incomplete coupling and
deprotection reactions lead to truncated and deletion sequences,
(b) accumulation of byproducts arising from incomplete reactions,
impurities from reagents, solvents and protected amino acids, and
(c) aggregation of growing peptides.
The efforts in the direction of overcoming the barrier on the
length of polypeptides as well as proteins have driven the syn-
thetic peptide chemistry towards a new dimension in the form of
ligation techniques.14 This approach harbours the potential of
overcoming the inadequacies of both solid- and solution-phase
protocols for the synthesis of proteins. In this technique, pre-
viously assembled large-peptide fragments are joined together
chemoselectively through the formation of an amide or non-
amide linkage.15 This method has the advantage of enforced
proximity between the two segments where the local effective
concentration of the reactants is high enough to overcome the
entropy barrier and hence facilitate the coupling. The ligation
protocol has the advantage of allowing unprotected peptides,
choice of reaction medium as organic or aqueous and synthesis on
solid or through solution phase. The ligation techniques are based
on three processes: an initial capture step, acyl migration and,
ﬁnally, release of the captured moiety (Scheme 1). Such chemo-
selective ligations are often based on employing thiol and imine
groups as reactive units to join the two fragments either through
amidic (peptide bond) or non-amidic linkages such as hydrazone,
oxime, thioester and thioether.16e18Kemp’s prior thiol-capture strategy, published in 1981, was
a seminal contribution to the concept of peptide ligation tech-
niques.19 It immediately attracted considerable attention from the
practitioners of peptide science as well as organic chemistry in
those days because the technique was far different from the then
prevailing conventional synthetic and semisynthetic methods and,
importantly, no enthalpic agents, enzymes, biologicals or protect-
ing groups were involved. In the method, a rigid template, 4-
hydroxy-6-mercaptodibenzofuran was used as the capturing moi-
ety to bring the peptide fragments into close proximity via a thio-
ledisulﬁde exchange reaction followed by an acyl transfer, thereby
establishing a new amide bond between the two fragments.
Cleavage of the captured moiety yielded a polypeptide with no
racemization at the ligation junction (Scheme 2). This strategy was
successfully implemented for the preparation of peptides of 25e40
amino acids in length.20
Chemoselective protein ligation began to blossom to its full
potential with the introduction of several strategies. Tam et al.
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H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e9537 9493developed an interesting route based on the reaction between
a peptide aldehyde and a Cys- or Ser/Thr-peptide, which led to
a stable ﬁve-membered 1,3-thiazolidine or -oxazolidine ring
through an imine intermediate.21 In the following step, thiazolidine
(or oxazolidine) undergoes a pH-dependent O/N acyl migration
into a peptide bearing a ﬁve-membered ring, which mimics proline
[thiaproline in the case of Cys (S-Pro), oxaproline in the case of Ser/
Thr (O-Pro)] and the technique was thus aptly named pseudopro-
line ligation (Scheme 3). Reaction of the peptide aldehyde with
other amines present, if any, such as those in the side chain of Lys
led to a reversible and unstable Schiff’s base.O
O
O
H
+ H2N
HX R
O
imine
capture
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O
N
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R
Scheme 3. Pseudoproline mediated ligation.An exceptional speciﬁcity of the reaction obviates the protection
of the side chains present in the peptide fragments. The pseudo-
proline residue thus formed at the ligation site restores the amide
backbone, but contains an additional 2-hydroxymethyl moiety. The
protocol was ﬁrst demonstrated for the synthesis of a pentadeca-
peptide by a 9þ6 convergent approach using a nonapeptide alde-
hyde22 (Scheme 4). The reaction was smooth and no byproducts
and side reactions were observed.Mass spectral analysis (observed:
1747 Da; calculated: 1747.7 Da) conﬁrmed the product. The protocol
was then successfully applied to obtain a 99-mer HIV-1 protease
analogue through a 38þ61 approach.23
Thiaproline ligation proceeds efﬁciently in both aqueous and
non-aqueous (pyridineeacetic acid) media. However, the oxapro-
line ligation requires anhydrous conditions and, even in this me-
dium, the thiaproline ligation is about 1000 times faster due to the
difference in basicity between eSH and eOH. The potential ofsolvent driven regioselectivity was utilized by Tam’s group for
tandem ligation of three or more unprotected peptides. In an ex-
emplary three-segment two-ligation experiment, Ser-Leu-Ile-Leu-
Asn-Gly-OCH2CHO and Cys-Phe-Lys-Ile-OHwere ligated selectively
in an aqueous buffer (pH 5.3) to yield the thiazolidine followed by
O/N acyl migration at pH 6.6, which was complete in 20 h (86%
yield). No reaction at the Ser end was reported during this step. The
resulting peptide, Ser-Leu-Ile-Leu-Asn-Gly-S-Pro-Phe-Lys-Ile-OH,
after puriﬁcation, was ligated to Asp-Ser-Phe-Gly-OCH2CHO in an
anhydrous pyridineeacetic acid medium. The reaction was com-
plete in about 35 h and the product, Asp-Ser-Phe-Gly-O-Pro-Leu-Ile-Leu-Asn-Gly-S-Pro-Phe-Lys-Ile-OH, was isolated in 78% yield
(Scheme 5).21a
Several peptide ligation strategies took birth with this success,
butmost of themwere conﬁned to the establishment of non-amidic
linkages between the peptide segments. Some of the important
protocols in this category are those that involved the formation of
thioester, oxime, thioether, disulﬁde and thiazolidine bonds. A list
of different ligation reactions yielding native and non-native amide
bonds is furnished in Table 1.24e32
Interestingly, the thioester forming ligation caught the attention
of Kent, who explored this simple reaction to synthesize the two
enantiomers of HIV-I protease enzyme employing all L- and all D-
amino acids (Fig. 1).33 The proteolytic activity was determined
through a ﬂuorogenic assay in which the enantiomeric enzymes
showed reciprocal chiral speciﬁcity in the hydrolysis of peptide
substrates, i.e., L-enzyme hydrolyzed the L-peptide substrate
H2N
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Scheme 5. Solvent driven tandem thiaproline and oxaproline ligations.
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Scheme 4. Synthesis of a 15-mer peptide through pseudoproline ligation strategy.
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e95379494exclusively and vice versa. With this landmark success, the chem-
ical synthesis of proteins progressed in leaps and bounds.
In the recent past, the techniques that deliver a native peptide
bond at the ligation site have continued to show exponential
growth.34 The present report discusses the ligation techniques with
respect to theunderlying chemistry, developments andapplicationof
each type of technique. Much emphasis has been placed on native
chemical ligation (NCL)35 due to its vast utility as well as its future
prospects inprotein assembly. Other contemporary ligationmethods,
expressed protein ligation (EPL)36 and Staudinger ligation,37 are also
delineated. The recently introduced concept, O-acyl isopeptide also
known as ‘click’ or ‘switch’ peptide method, useful for the chemical
assembly of highly aggregation-prone polypeptides, is dealt with.38
Readers are referred to several reviews and articles on these con-
temporary approaches for further insights.24e26,39
2. Native chemical ligation
In 1994, Kent et al. developed the innovative idea popularly
known as ‘native chemical ligation’. It was an ingenious extensionof the thus-far developed chemistries for the chemoselective re-
action of two unprotected peptide fragments (Fig. 2).28 In the ﬁrst
disclosure, they described the reaction of an unprotected synthetic
peptide-a-thioester with another unprotected peptide segment
containing N-terminal Cys to generate a thioester-linked in-
termediate, which spontaneously underwent an intramolecular
acyl migration to afford a native peptide (Scheme 6).
A platform for the NCL was laid as early as 1953 by Wieland
when he observed that Val-SPh reacted with Cys in aqueous buffer
to furnish the dipeptide Val-Cys (Scheme 6).40
A long time elapsed, however, until it struck the attention of Kent
and Dawson28 to turn it into major protein synthesis tool. A simple
reaction is converted into a robust technique, which is a practically
viable strategy for ligating two large polypeptide fragments. The
reaction can be carried out in neutral or slightly basic pH and in the
presence of guanidiniumhydrochloride (Gnd$HCl), which acts as an
aid to prevent aggregation of the peptide fragments. Although the
exact mechanism has not been proved unarguably, based on the
available experimental evidence and common observations, it is
believed to involve the route shown in Scheme7,where theﬁrst step
is a transthioesteriﬁcation involving the sulfhydryl group of Cys and
peptide-a-thioester and the second step is an S/N acyl migration
resulting in peptide bond formation.41The former step is reversible and rate determining, and de-
pends on the nature of the substituent present on the leaving thiol
moiety. In the presence of endo-Cys residues in either segment,
free 3-amino, phenolic hydroxy, indole, imidazole or guanidine
groups are not acylated, since the reaction is too selective for
terminal Cys. Consequently, no byproducts are formed. Kent
opines that the modest enthalphic activation of the peptide thio-
ester, the use of pH 6.8e7.0 and the stability of the thioester
moiety towards hydroxide or hydroxy nucleophiles contribute to
such excellent chemoselectivity.35a The practical utilization of NCL
owes its effectiveness to the unique properties of thioesters, which
are stable to hydroxide-catalyzed hydrolysis, but very much sus-
ceptible to thiolysis and aminolysis. This stabilityelability combi-
nation yields an adequate selectivity in NCL. Some important
features of NCL are listed below:
➢ This robust reaction is so highly chemoselective that it occurs
only at the N-terminal Cys residue.
➢ The thioesters formed at other Cys residues are reversible and
unproductive.
Table 1
Selected ligation techniques
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e9537 9495
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Fig. 1. Chemical assembly of HIV-1 protease.
Fig. 2. A schematic representation of peptide ligation.
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unprotected segments are ligated under physiological con-
ditions (near neutral pH).
➢ The mild thioester activation, non-basic reaction conditions
and intramolecular mechanism of amide formationmake NCL
a racemization-free event.
➢ Thiol additives such as benzyl 2-mercaptoethanesulfonate
and thiophenol are added to the reaction mixture to keep
other thiol functional groups, if any, under a reduced state
and to circumvent any undesired disulﬁde formation.
➢ Aryl thioesters are more reactive than alkyl thioesters. Hence,
in the case of alkyl thioesters, some exogenous thiols such as
benzyl mercaptan and 2-mercaptopyridine are used to pro-
mote the in situ formation of ‘active thioesters,’ thus in-
creasing the kinetics of ligation.
➢ Ligations at sterically hindered C-terminal residues such as
Val or Ile are slower, compared to the less-hindered Ala and
Gly. The reaction at the latter occurs rapidly in minutes, while
that at the former takes hours and, sometimes, days for
completion.
In effect, the Cys-thioester-linked intermediate plays a key role,
which after S/N acyl migration yields the target protein. However,
attempts to trace the formation of the thioester intermediate by
using HPLC techniques have not yielded any good results so far.26 A
summary of the protocols for the synthesis of thioesters42 is given in
Scheme 8. Nowadays, NCL is a deﬁning point in establishing che-
moselective ligation as a general synthetic route for the chemical
assembly of proteins. This approach is enjoying vast attention, be-
cause of the development of general access to peptide-a-thioesters.
Automation and advancements in SPPS essential for preparing the
peptide fragments have strengthened the hands of researchers in
achieving the success of NCL to an even greater extent.R
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Scheme 8. Pathways to transthioesteriﬁcation.2.1. Case studies of protein synthesis via NCL
In the very ﬁrst report on NCL, Kent et al. demonstrated the total
synthesis of human interleukin, a 72-amino acid protein.28 The
presence of Cys at position 34 facilitated this synthesis through
a 33þ39 convergent approach. This success triggered numerous
reports on the application of NCL for the synthesis of proteins.
Kent group reported the synthesis of turkey ovomucoid third
domain (OMTKY3), a potent protein inhibitor of most serineproteinases.43NCLwas thekey tool to assemble theactivepart (6e56)
of this peptide. Notably, the protein contains three Cys residues in the
sequence at positions 24, 35 and 38, which allow a wide choice for
selection of the ligation site (Fig. 3). A ligation ofOMTKY3(6e23)with
OMTKY3(24e56)wasdesignedat theCys24 junction and the required
fragments were prepared employing Boc-Cys(p-MeBzl)OCH2-phe-
nylacetamidomethyl (PAM) resin using tert-butoxycarbonyl (Boc)/2-
(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexaﬂuorophos-
phate (HBTU) chemistry. Ligationwas carried out using 0.25mmol of
each fragment in6MGnd$HCl in thepresenceof1%benzylmercaptan
and 3% thiophenol at pH 7.5 for 36 h to afford OMTKY3 in 56% yield
(75 mg), the molecular weight of which, determined by ES-MS
(5579.80.8 Da), matched the calculated value (5579.3 Da).In order to determine the possibility of racemization at the
C-terminal residue during ligation, a model study of the ligation
site Leu23-Cys24 was carried out. OMTKY3(14e23)-aCOSBzl was
ligated to OMTKY3(24e33) to afford OMTKY3(14e33). A reference
compound, OMTKY3(14e33)-D-Leu23, was synthesized on 4-methylbenzhydrylamine (MBHA) resin by the routine SPPS route
and used as the standard. Comparison of the HPLC chromatograms
of the two diastereomers revealed that no detectable racemization
had occurred (<1%).43
For the synthesis of human group II secretory phospholipase A2
(sPLA2), a 124-amino acid residue enzyme found in a-granules of
platelets and inﬂammator sites, three possible ligation junctions
are available, at Asp48-Cys, Gly58-Cys and Thr76-Cys. The junction at
position 58 was chosen to utilize the advantage of least steric
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e95379498hindrance offered by the Gly residue (Fig. 4). The synthesis was
performed by ligating PLA2-(1e58) (9 mg/ml, 0.4 mmol) with PLA2-
(59e124) (9 mg/ml, 0.4 mmol).44 The reaction was complete in
about 22 h, as monitored by ES-MS and HPLC. ES-MS analysis of the
crude sample conﬁrmed the presence of the 124-amino acid pro-
tein chain (13,919.51.6 Da; calculated value 13,918 Da).1-NLVNFHRMIKLTTGKEAALSYGFYGCHCGV
31-GGRGSPKDATDRCCVTHDCCYKRLEKRGCG
61-TKFLSYKFSNSGSRITCAKQDSCRSQLCEC
91-DKAAATCFARNKTTYNKKYQYYSNKHCRGSTPRC
ligation
junction
Fig. 4. Sequence of human type II secretory phospholipase A2.The product was puriﬁed through preparative HPLC and folded
to afford the protein sPLA2, which had a mass of 13,904.7þ0.8 Da
(calculated value 13,904 Da). The decrement of 14 Da in the mass
value, as expected, was due to the formation of seven disulﬁde
bridges during folding. The synthetic protein was found to possess
both enzymatic and anticoagulant activities.
Lu et al. accomplished the chemical synthesis of a 100-aminoacid
protein, human psoriasin (S100A7), employing NCL.45 S100A7 is
amember of the S100 family of calcium-binding proteins, expressed
abundantly in the keratinocytes of psoriasis patients. The occur-
rence of a Cys residue at position46 allows the convenient ligation of
two almost equal-length peptide fragments, Ps(1e45)-a-COSR and
Ps(Cys46-100). The fragments were prepared on solid phase using
Boc chemistry. The NCL carried out on a 14-mmol scale under stan-
dard conditions afforded 74 mg of the ﬁnal product, corresponding
to 46% yield (Fig. 5). The molecular mass of the reduced form of
psoriasin as analyzed by ESI-MS was 11,367.92.0 Da, which is in
agreement with the calculated value (11,367.8 Da).
After oxidation and folding, the ESI-MS of the proteinwas found
to be 11,365.71.3 Da in agreement with the calculated value of
11,365.8 Da. The difference of 2.2 Da from the reduced form is due
to the formation of one disulﬁde bridge. Psoriasin is known to be
a potent destroyer of Escherichia coli. The antimicrobial activity of
synthetic psoriasin was tested against E. coli ATCC 35218 using
a standard colony-counting assay. A dose dependent antimicrobial
activity was observed with an LD90value of 15 mg/ml or 1.3 mM,
which is comparable to the reported value (0.5 mM) for natural
psoriasin (Fig. 6; percentage of killing is expressed relative to
bacteria incubated with buffer alone for 3 h at 37 C).
Paramonov et al. synthesized high-molecular-weight colla-
gen-like polymers through self-propagated NCL sequences.46 In
tissue engineering, collagen-like polymers play a pivotal role infurnishing chemical and biological information on extracellular
matrix and its conventional synthesis is intricate due to the
large size (>1000 amino acid residues) and other synthetic
problems. In the ﬁrst step, the repeating-unit peptides equip-
ped with thioester moieties on the C-termini and Cys on the N-
termini were prepared and then subjected to intermolecularnative chemical ligation in parallel experiments (each in-
dividual peptide 3 mg/ml in 10 mM phosphate buffer, pH: 7.3,
3 mg/ml dithiothritol, 10 h) to afford the high-molecular-
weight collagen polymers (Scheme 9). Chain termination was
induced as and when desired by hydrolyzing the terminal
thioester moiety. Thus, the synthesis of polymers of molecular
weight up to 1,660,000 Da, as determined by MALDI-MS, was
achieved.
The utility of NCL has also been extended to synthesize multi-
valent protein and peptide dendrimers.47 These hyperbranched
polymers with a high density of functional groups are attractive
scaffolds in drug-delivery systems. Meijer et al. employed NCL to
prepare dendrimers of multiple antigen peptides (MAPs) contain-
ing 2e8 peptide chains.48 For this, three different sized poly(-
propyleneimine) dendrimers were selected as substrates and the
terminal amino groups were functionalized with Cys by reacting
with Trt-Cys(Trt)-OSu. Removal of Trt groups opened the den-
drimers for NCL with peptide-a-thioesters. Ligation with Ac-Leu-
Tyr-Arg-Ala-Gly-mercaptopropionic acid-leucine (Ac-LYRAG-
MPAL) afforded a dendrimeric peptide tetramer, octamer and
hexadecamer based on the number of Cys residues present on the
dendrimer scaffold (Scheme 10).
Fujita et al. assembled highly pure lipopeptides with different
peptide antigens over diverse branches of the lipid core peptide
system (LPS).49 The LPS consists of a lipid adjuvant at the C-terminus
and conjugated through its N-terminus to an oligolysine multiple
copies of oneormorepeptide antigens. Suchmolecules arepotential
multi-epitope vaccine candidates. NCL was effectively used to con-
jugate different antigens to the Lys tail of LPS through proper
selection of protecting groups for the Cys residues (Scheme 11).
By employing orthogonal protections on each of the Cys residues, up
to four different epitopes can be ligated into the lipid core.
Fig. 5. HPLC chromatogramsof ligationmixture: (A) before commencement of reaction and (B) after 6-h ligation. (C) ESI-MSof reducedS100A7. (D)Oxidized and folded formof S100A7.
Fig. 6. Antimicrobial activity of synthetic psoriasin.
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proteins, secretory proteins, adopter domains from intracellular
signalling pathways, transcription factors and electron-transfer
proteins have been synthesized via the NCL. The inexhaustive
repertoire runs to more than 400 examples, some of which are
furnished in Table 2.
Reports on the application of NCL to assemble hydrophobic
peptides are scarce due to the synthetic challenges and difﬁculty in
the isolation of hydrophobic peptide thioesters. Nevertheless, this
area has been addressed by Naider, who reported the synthesis of
fragments of G-protein coupled receptors (GPCRs). Determination
of structural information on GPCRs has proven to be extremely
challenging, due to their resistance to crystallization and the in-
ability to examine them using high-resolution NMR techniques.Hence, short segments of GPCRs are being employed to understand
the mechanism of action. NCL was adopted for the synthesis of
peptides corresponding to the major portion of sixth and seventh
transmembrane domain (TM6 and TM7) and a loop sequence
connecting these two domains, the third extracellular loop (EL3).552.2. Synthesis of peptide-a-thioesters
The development of an efﬁcient method for the synthesis of
peptide-a-thioesters is critical to the success of NCL.56 Conven-
tional protocols are based on Boc-SPPS chemistry on a thioester-
functionalized resin.57 However, the repetitive acidolysis step in-
built in Boc chemistry as well as the harsh cleavage conditions re-
quired for the cleavage of peptide-a-thioesters from the solid
support (usually anhydrous liquid HF with scavengers) have in-
herent limitations, especially when acid-sensitive groups such as
glycol, phosphono, etc. are present.58,59 Switching over to Fmoc
chemistry, as such, is not a viable route, due to the lability of
a thioester linkage to the basic conditions employed for Fmoc re-
moval after each coupling cycle. To address this issue, mild reagents
have been employed for the cleavage of Fmoc groups, so as to keep
the thioester linkage intact. Reagent systems such as: (a) a cocktail
of 2% hexamethyleneimine, 2% 1-hydroxybenzotriazole (HOBt) and
25% 1-methylpyrrolidine in a mixture of N-methyl-2-pyrrolidone
(NMP) and DMSO,60 and (b) a non-nucleophilic base, 1,8-
diazabicyclo[5,4,0]undeca-7-ene (DBU), in combination with
HOBt in N,N0-dimethylformamide (DMF)56b have shown minimal
decomposition of the thioester linkage during Fmoc cleavage. Apart
from this, a handful of ingenious solid-phase protocols have also
been developed, some of which are discussed below.
Bertozzi et al. demonstrated the synthesis of peptide-a-thio-
esters by Fmoc chemistryemployingmodiﬁedKenner’s sulfonamide
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Scheme 9. Synthesis of collagen polymers via repetitive intramolecular NCLs.safety-catch linker.54 In this route, the carboxy group of the ﬁrst
amino acid is anchored to the resin via an acid- and base-stable N-
acyl sulfonamide linkage followed by peptide assembly. For the
detachment of the assembled peptide from the solid support, the
sulfonamide moiety is activated by cyanomethylation and thepeptide is released as a thioester by treating with thionucleophiles
such as thiophenol. During the synthesis of an analogue of the an-
tibacterial glycoprotein, diptericin, the thioester segment, Thr10(Ac3-
a-D-GalNAc)diptericin(1e24)-COSBn, was assembled through this
strategy. Initially, Fmoc-Gly24 was loaded onto 4-sulfamylbutyryl
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Scheme 11. Utility of NCL for tailoring lipopeptides.
Table 2
Proteins synthesized through NCL
Protein Chain
length
Mol. wt.
(kDa)
Ref.
Secretory
Chemokines 72 8e10 28
Ser PR inhibitors 58e70 6e8 43
Anaphylatoxins 70 8 50a
AGRPs 46e112 7e15 50b
Phospholipase A2 124 13 35b
Proteases
HIV-1 299 18 18
Flap engineered HIV-1 299 18 50c
Inﬂuenza A virus M2 97 10e11 50d
Histone 135 14 50e
Zinc ﬁnger protein Zif268 81 11 51
Chymotrypsin inhibitor 2 64 7 50f
Enzymes
Macrophage migration inhibitory factor (MIF) 115 39 52
Barnase 110 12 26b
Bovine ribonuclease 124 12e13 10
Receptors
b2 Microglobulin 99 12 50g
CC chemokine CL14/HCC-1 66 8 50h
Intracellular
b/HLH/Z 2150 16e20 50i
Zn-ﬁnger 70 8 50j
Redox
Rubredoxin 53 6 50k
Cytochrome b5 82 9 50l
Cytochrome b562 106 12e13 53
Antibacterial
Diptericin (glycoprotein) 82 7e8 54
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e9537 9501aminomethyl (AM) resin using (1H-benzotriazol-1-yloxy)tripyrro-
lidinophosphonium hexaﬂuorophosphate (PyBOP)/N,N-diisopro-
pylethylamine (DIEA) and subsequent chain elongation was carried
out using Fmoc/DCC/HOBt chemistry. After the ﬁnal coupling step,
the resin-bound peptide was alkylated using iodoacetonitrile to af-
ford the corresponding N,N-cyanomethylacylalkanesulfonamide
active ester. The peptide was cleaved as the peptide-a-thioester by
treating with benzyl mercaptan followed by removal of the Boc and
other side chain protecting groups using reagent K (82.5% TFA, 5%
phenol, 5% water, 5% thioanisole and 2.5% EDT; Scheme 12). The
crude product was puriﬁed by RP-HPLC to afford the peptide-a-
thioester in 21% yield (ES-MSdetermined: 2843Da; calculated value
2844.15 Da). The above strategy was also followed by Pessi et al. for
the synthesis of peptide-a-thioesters such as MWAGADPA-SR,
AEGEFMRASRCN PNCPMWAGADPA-SR, KKKSTWVLVGGVLAA-
LAAY-SR [R¼e(CH2)2eCO2Et].61
A strategy involving an intramolecular N/S acyl shift was
developed for the synthesis of peptide-a-thioesters on sul-
fonamide safety-catch linker.62 The peptide was assembled on
a 3-carboxypropanesulfonamide linker through Fmoc/tert-butyl-
SPPS. The acylsulfonamide nitrogenwas alkylated using Mitsunobu
chemistry with a mercaptoethanol derivative. Removal of the trii-
sopropylsilyl moiety exposed the free thiol group, which triggered
the N/S acyl shift, furnishing the desired peptide-a-thioester at-
tached to the solid support (Scheme 13). It was either cleaved from
the solid support to afford the peptide-a-thioester or used directly
for on-resin NCL.
Barany et al. introduced a new route for the solid-phase synthesis
of peptide thioesters using a backbone amide linker (BAL).63 The key
aspect in this study is that thegrowingpeptide is attached to the solid
support through the aminogroup of theﬁrst aminoacid. The carboxy
terminus of the ﬁrst amino acid is kept protected usually as the allyl
ester throughout the synthesis. After the assembly of thepeptide, the
allyl group is removed and the carboxyl is then either directly thio-
esteriﬁed or coupled to an amino acid thioester (Scheme 14).
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H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e95379502Another interesting BAL-based approach was reported from
Albericio’s laboratory.64 A key step in this protocol is to introduce
aGly-derived amino trithioester into theBAL support and subsequent
chain elongation on the N-terminus of the Gly-derived trithioester.
The trithio group is resistant to nucleophilic attack and, hence, is
compatiblewith Fmoc chemistry. After the complete assembly of the
peptide, a universal cleavage step is carried out employingtriﬂuoroacetic acid (TFA) to afford the free peptide thioester
(Scheme 15). In a typical example, the synthesis of Phe-Val-Lys-Glu-
Tyr-Ala-Gly-SEtwas demonstrated,whichwas isolated in 42% overall
yield.
A simple chemistry for on-resin generation of peptide thio-
phenyl esters was reported by Kent et al. employing a p-methyl-
benzhydrylamine (MBHA) support.65 S-Tritylmercaptoacetic acid,
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H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e9537 9503prepared by the reaction of 4-mercaptoacetic acid with trityl
chloride (TrteCl), was coupled to the resin-bound Gly. Following
the removal of Trt protection employing triisopropylsilane, peptide
assembly was carried out employing Boc chemistry. At the end of
the procedure, the assembled peptide thiophenyl ester was cleaved
from the resin support using anhydrous liquid HF (Scheme 16).HS
OH
O Ph3CCl S
OH
O
NHH-Gly
NHGly
S O
Trityl
removal
NHGly
HS O
Boc-Xaa-OH
SPPS
NHGly
S OPeptide
Boc
HF
Gly
S OPeptide
OH
liquid
HBTU,
DIEA
anhydrous
Scheme 16. Peptide-a-thioester synthesis via Boc-SPPS on MBHA resin.Recently, Sharma and Crich developed a novel strategy for the
synthesis of peptide-a-thioesters.66 The Fmoc chemistry-compatible
method involved assembling a peptide onto a glycylaminomethyl
resin via a thioglycinamide bond. An Fmoc-Xaa-Gly-OtBu was thio-
nated and the resulting thiopeptide was attached to the resin via an
amide bond. After chain elongation, the thioamide was alkylated
with benzyl bromide to afford the corresponding thioimide, which
on treatment with TFA led to the release of peptide from the resin as
the corresponding thioester (Scheme 17).
Apart from a variety of chemical methods, recombinant syn-
thesis has also been developed as an alternative and efﬁcient ave-
nue for accessing large polypeptide thioesters.67 Studies on protein
splicing have enabled the scission of large-peptide fragments as the
corresponding thioesters through bioengineering.42
2.3. Convergent synthesis through multiple ligations
Although NCL is undoubtedly the predominantly practiced
protocol for the ligation of two peptide fragments, high-molecular-weight protein synthesis has remained a daunting task, due to the
limitations of the prevailing protocols (such as SPPS) for the
preparation of the large ligatable segments required for the as-
sembling. This problem, however, was addressed to a certain extent
by performing the convergent ligation of multiple fragments.68
Thus, in a typical protocol, two fragments are ligated ﬁrst. Theresulting intermediate polypeptide is then subjected to ligation
with another fragment and so on. Of considerable concern in this
strategy is that the middle fragments would bear Cys at the N-
terminus and thioester at the C-terminus, which would result in
undesired byproducts through intramolecular ligations. To combat
this, either of the two termini must be masked temporarily while
operating at the other end. Soon, strategies were also developed to
carry out the tandem ligations in a one-pot fashion by modulating
the reaction conditions, usage of proper protecting groups and
controlling the reaction kinetics.
Kent et al. synthesized snow ﬂea antifreeze protein (sfAFP, an 81-
amino acid sequence) employing four-segment three sequential li-
gations.51 The polypeptide chain of sfAFP contains Cys residues at
positions1,13, 28and43. Its sequencewasdissected into fourpeptide
segments, [1e12], [13e27], [28e42] and [43e81], which were pre-
pared through conventional SPPS. During the course of the synthesis,
initially the third and the fourth segments were ligated keeping the
Cys28 of the third segment protected as 1,3-thiazolidine-4-
carboxylate (Thz). The resulting fragment, Thz28-Pro81, was puriﬁed
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amine hydrochloride (pH 4.0) and then ligated to the Thz13-Gly27
fragment. Finally, ligation with the ﬁrst segment, [Cys-Gly12], was
carried out (Scheme 18). All the ligations were carried out in Na2PO4
buffer in the presence of 6 M Gnd$HCl, pH 6.8 and a thiol. Using
a similar strategy, the other enantiomer, D-sfAFP, was also synthe-
sized. All the fragments were assembled on a 0.4mmol scale. D[Thz1-
Gly12] was obtained in 33% yield (80 mg); D[Thz13-Gly27] (100 mg)
and D[Thz28-Gly42] (45 mg) in 22.5% yield; and D[Cys43-Pro81] in 41%
yield (300 mg). Both L- and D-isomers were folded separately in
phosphate buffer (pH7.8) in thepresenceof 8mMcysteine and1mM
cystine$HCl at 4 C. Ice recrystallization inhibition studies conﬁrmed
that both the proteins bear similar antifreeze activities.Thz-1-12-COSR Thz-13-27-COSR Thz-28-42-COSR Cys--43-81-COOH
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Scheme 18. Synthesis of sfAFP along with mass spectra of L- and D-isomers of folded protein.Beligere andDawson successfullymade a transcription factor zinc
ﬁnger protein, Zif268, employing NCL.69 Zif268 contains three DNA
binding ﬁnger domains, due to which it recognizes a broad range of
DNAsequences.A two-step, three-segmentapproachwas followed toassemble this 90-amino acid chain. The Cys residues at positions 37
and 65 were chosen as ligation centres and the fragments, Zif(1e36)
(MERPYACPVESCDRRFSRSD-ELTRHIRIHTGQKPFQ), Zif(37e64)
(CRICMRNFSR SDHLTTHIRTHTGEKPFA) and Zif(65e90) (CDICGRK-
FARSDERKRHTKIHLRQKD), were synthesized by manual SPPS. Step-
wise ligation was performed, during which, initially, 1.7 mM of
Zif(37e64) was ligated to 1.7 mM of Zif(65e90) under the usual li-
gation conditions by keeping Cys37 protected with an Msc (methyl-
sulfonylethoxycarbonyl) group to circumvent undesirable self-
ligation. After removing the protection of Cys37, the resulting
Zif(37e90)was isolated in 34% yield (3.7mg), whichwas then ligated
to 0.93mMof Zif(1e36) to afford 1.75mg of Zif268 in an overall yield
of 30%.During the synthesis of crambin (46-amino acid residue), the
usual approach of bisegment coupling between Cram[1e15]þCram
[Cys16-46] turned out to be low yielding. There are two forms of
crambin, which differ by the amino acids present at positions 22
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e9537 9505and 25. One having Ser22 and Ile25 is known as the SI form, while
the other with Pro22 and Leu25 is called the PL form. When these
proteins were assembled through NCL, both products were found to
have a major impurity of the analogous peptide with one Thr res-
idue less. Careful studies revealed that this was due to the deletion
of Thr21 during SPPS, the incorporation of which required at least
three repeated couplings. Consequently, Kent employed a three-
segment two-ligation strategy. It was demonstrated by the as-
sembly of the PL form of crambin [i.e., via (Cram(1-V15A)COSRþ-
Cram(Cys(Acm)16-Gly31)COSR)þCram(Cys32-Asn46)].70 The thiol
group of the Cys16 residue of the middle fragment was blocked
employing an acetamidomethyl (Acm) group until the completion
of ﬁrst ligation with Cram(Cys32-Asn46), the third segment. The li-
gation of the middle and the third segments was complete in about
6 h. The product was isolated and the Acm group was removed to
afford Cram(Cys16-46), which, in the last step, was ligated to the
ﬁrst segment, Cram(1-V15A)COSR, to obtain the full-length linear
peptide in 70% yield after puriﬁcation (Scheme 19). In the ﬁrst
segment, V15 was replaced with Ala to ease the steric hindrance
during ligation. The polypeptide was subjected to folding in 2 M
Gnd$HCl (about 1 h) and then puriﬁed to afford the protein in 80%
yield based on the linear peptide (Fig. 7).Scheme 19. A three-segment two-ligation strategy applied for the synthesis of crambin.In a separate synthesis, Bang and Kent demonstrated a one-pot
assembly of crambin71 via a three-segment two-ligation strategy
similar to that described above with the difference that Cys16 of the
middle fragment was protected with an acid-labile Thz moiety in-
steadofAcm. The ligationbetweenCram[Thz16-Gly31]COSRandCram
[Cys32-Asn46] was carried out on a 0.4 mol scale, which took about
20 h to complete. The resulting product, Cram[Thz16-Asn46], withoutisolation, was treated with 0.2 M methoxyamine hydrochloride to
convert it into thedesiredCram[Cys16-Asn46] and thenligateddirectly
to Cram[1e16]COSR at pH 7.0 to obtain the full-length peptide. By
proper tuning of the reaction conditions, protein folding was also
accomplished in the same ﬂask to afford crambin in 45% overall yield
(12.5 mg). This protocol reduced the reaction time, eliminated the
intermediate puriﬁcation step and also elevated the overall yield.
Several protecting groups have been proposed for protecting Cys
of the middle fragments during multisegment ligations.72 However,
such strategies necessitate the cumbersome isolation of free Cys-
peptide from the excess reagents used for deprotection. Interestingly,
Otaka et al. developed a photolabile N-protector for Cys, which was
used in the tandem ligation of multiple segments.73 After screening
several derivatives of 4-(dimethylamino) esters, 4-(dimethylamino)
phenacyloxycarbonyl (Mapoc) was found to be useful. Its utility in
NCL was demonstrated by synthesizing the 32-amino acid human
brain natriuretic peptide (hBNP-32; Scheme 20). The middle frag-
ment, Na-Mapoc-Cys10-25, and the third fragment, Cys26-32, were
ligated in the presence of 0.3% thiophenol in phosphate buffer (pH
7.6) and Gnd$HCl. The fragment, Mapoc-Cys10-32, without isolation,
was subjected to photoirradiation (100 W, high pressure, Hg lamp,
hn>300 nm) for 30 min to cleave the Mapoc group and then thesecond ligation was carried out with (Ser1-9)-SEt to obtain the
complete peptide. Folding was also accomplished in the same ﬂask
by diluting with phosphate buffer followed by the addition of DMSO
to afford the desired natriuretic peptide in 56% yield.
Bang and Kent developed a novel His6 tag-based approach for
carrying out multiple ligations.74 The C-terminal-His6 tag facilitates
the isolation and handling of the intermediates. In principle, the
Fig. 7. (A) and (C): HPLC and mass spectra of puriﬁed crambin. (B) and (D): HPLC and mass spectra of crambin (PL form) after folding.
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Scheme 20. Photolabile protecting group on the N-terminal Cys of the middle fragment facilitates multisegment ligations.
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ligation with a Pg-Cys-peptide-2-COSR. At the end of the reaction,
the SH protector is released and the peptide adsorbed on to
a NieNTA (nickelenitriloacetic acid) agarose column (the His6 tags
have high afﬁnity towards this column). The undesired materials
were washed, and, ﬁnally, the peptide-His6 was eluted from the
column using imidazole. At this stage, the product can either be
isolated or subjected again for ligation with another Pg-Cys-
peptide-COSR and so on. This ligation chemistry was demon-
strated by the synthesis of crambin through a three-segment two-
ligation approach (Scheme 21).
After the ﬁnal ligation, the full-length peptide adsorbed on to an
N-agarose support was subjected to folding. It was properly washed
and the crambin-His6 was eluted from the column.
The His6 tag-assisted NCL was also employed for assembling
the repeat protein of a 34-amino acid sequence, Thz-
AWYNLGNAYYKQGDYDEAIEYYQKALELDPNNA-thioester, into its
trimer (repeat proteins are formed from multiple copies of the
same fragment).74
2.4. Solid-phase ligation (SP-NCL)
To increase the multiple-segment ligation efﬁciency and also to
minimize repetitive puriﬁcation steps and lyophilization of in-
termediates, thus circumventing the handling losses, a solid-phaseligation techniquewas developed.72 The prerequisites are a suitable
choice of resin linker, solid support and protecting groups.
Employing a stable safety-catch acid-labile (SCAL) linker, the syn-
thesis of vMIP-I, a 71-amino acid viral chemokine was accom-
plished via SP-NCL. To perform the sequential ligation on solid
phase, the polypeptide sequencewas dissected into three segments
as vMIP-I(1e12), vMIP-I(13e35) and vMIP-I(36e71). The C-termi-
nal segment was synthesized on a thioester resin with Gly-Gly
spacer and SCAL linker. The other two segments, vMIP-I(1e12)
COSR and vMIP-I(13e35)COSR, were separately prepared on solid
phase; Cys13 and Cys36 were protected as the corresponding Msc
derivatives. vMIP-Msc-(36e71)-SCAL-Gly-Gly-COSR was ﬁrst at-
tached to Cys-sepharose through NCL. After the removal of Msc
protection on Cys36, the middle segment, vMIP-Msc(13e35)COSR,
was ligated. The deprotection and ligation cycle were repeated to
attach the vMIP-I(1e12) segment also. The progress of the ligation
was monitored through HPLC by following the peptide-a-thioester
consumption. The cleavage of the peptide from the linker afforded
vMIP-I(1e71). The whole set of ligation sequences was complete
within 30 h (Scheme 22).
Kent’s group demonstrated the solid-phase ligation of un-
protected peptide segments from the N/C direction (i.e., starting
from the polymer-bound N-terminal segment towards the C-termi-
nus of the target polypeptide chain) aswell as in the reverseway, i.e.,
C/N direction (polymer-bound C-terminal segment towards N-
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Scheme 21. C-Terminal-His6 tag facilitates multiple ligations through simpler isolation
of the intermediate peptides.
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Scheme 22. Sequential ligations on solid support.
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e9537 9507terminus of the polypeptide chain).52 In the N/C ligation strategy,
the middle segments were prepared as the corresponding Cys-
peptide thiocarboxylates. The presence of thiocarboxylic acid in the
form of thiocarboxylate ion itself serves as protecting group tempo-
rarily and allows for the selective and smooth ligation at the N-Cys
peptide termini.After ligation, the thiocarboxylatewasconverted into
the reactive thiocarboxylic ester by treating with bromoacetic acid in
water and this was then subjected to ligation with another Cys-
peptide thiocarboxylate. In the penultimate step, the ﬁnal ligation
was accomplishedwith Cys-peptide acid and then detached from the
resin followed by HPLC puriﬁcation and folding (Scheme 23).
This strategy was demonstrated by assembling human C5a
(a 74-amino acid plasma protein with potent chemoattractant
and proinﬂammatory properties) employing three fragments,T1LQKKIEEIAAKYKHSVVKK20-COSH, C21CYDGACVNNDETCEQRAAR-
ISLGPK46-COSH, and C47IKAFTECCVVASQLR-ANISHKDMQLG73R.
In order to carry out the ligation in the C/N direction, Cys-
peptide was anchored on to a solid support and a Pg-Cys-peptide
thioester was ligated under standard conditions. In the sub-
sequent steps, the thiol protector of Cyswas released and unreacted
substrates and excess reagents were washed off. The peptide as-
sembly was continued by ligating another Pg-Cys-peptide thioester
to the resin-bound Cys-peptide. Cycles of ligation and deprotection
were performed to assemble large polypeptides. Importantly,
polypeptides obtained after series of ligation reactions were free
from stereomutation.
2.5. Kinetically controlled NCL (KCL)
Another remarkable contribution by Kent’s group to the con-
vergent synthesis of proteins is the development of KCL.75 In the
tandemmultisegment ligations, initially two peptide fragments are
introduced to the reaction vessel and ligated. The third peptide
fragment is introduced only after the completion of the ﬁrst liga-
tion. This multistep approach is necessary because of the practical
difﬁculty of controlling the dual reactivity of Cys-peptide-COSR
fragments. However, it has been established that the peptide
alkylthioesters are relatively unreactive and the addition of thio-
phenol as catalyst increases their reactivity by forming an ‘active’
thiophenolic ester.75 Thus, it was envisaged that, in an uncatalyzed
competitive reaction between a peptide thioalkyl ester and a pep-
tide thiophenyl ester, the latter would ligate with a Cys-peptide
preferentially leaving the alkylthioester unperturbed. This reﬁned
strategy was applied for the assembly of crambin using a six-frag-ment ligation protocol (Scheme 24). The ﬁrst, second and third li-
gations were carried out in the absence of the thiophenol catalyst
so as to direct the ligations only at the phenolic thioesters, during
which the alkylthioester termini remained unreactive. The fourth
and ﬁfth ligations were performed in the presence of the thiol
additive to activate the alkylthioesters. The yield for the ﬁrst liga-
tion and subsequent conversion of Thz into Cys was 71%, that for
ligation 2was 50%, 80% for ligation 3 alone but 40%when ligations 3
and 4were carried out in one pot, and 62% for ligation 5 followed by
folding.
Human lysozyme (a 130-amino acid sequence) was also as-
sembled through a four-segment KCL.76 Lysozymes serve as model
systems in various areas of biomedical research including protein
folding and enzyme catalysis. It was assembled via the ligation of
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the protein was fragmented into four almost equal-length poly-
peptidesd(1e29), (30e64), (65e94) and (95e130). All the frag-
ments were synthesized employing in situ neutralization by Boc
chemistry/SPPS. Ligations were carried out in 6 M Gnd$HCl and
0.2 M sodium phosphate buffer. After the completion of four liga-
tions, the ﬁnal peptide was puriﬁed using RP-HPLC (Fig. 8) and was
characterized through mass spectroscopy (found: 14,700.21.5 Da;
calculated: 14,700.7 Da). In the ﬁnal step, the polypeptide was
subjected to folding in a redox system (5 mM oxidized glutathione
and 2 mM DTT at pH 8.0). It was lyophilized to afford 2.5 mg of the
protein in an overall yield of 40% (Fig. 8).
2.6. Ligation at Glu/Asp-Cys site and limitations
NCL, in general, was considered to be feasible with peptide-a-
thioesters having any of the 20 natural amino acids at the C-ter-
minus by which access to any Xaa-Cys sequence at the ligation
junction is possible.35b However, careful studies revealed that this
is not so if Asp/Glu is present at the C-terminus. The presence of a b/
g-carboxy group in proximity to a thio ester results in themigration
of the thioester moiety onto the side-chain carboxy group. This
leads to an anhydride intermediate and the outcome of this wouldbe a mixture of a-Cys-peptide and u-Cys peptide (Scheme 26). This
necessitates the use of a suitable protector for the side-chain car-
boxy moiety of Asp/Glu when present at the C-terminus. Botti et al.
envisaged that such protecting groups must be easy to introduce
and remove, and stable to cleavage and ligation conditions.77,78 9-
Fluorenylmethyl ester (OFm), (phenylsulfonyl)ethyl ester (OPse)
and a couple of protecting groups were thus explored and their
utility in NCL was demonstrated. However, Fm and Pse groups are
not suitable for Fmoc-SPPS chemistry owing to their base lability.
To combat this, Briand et al. developed a photolabile protecting
group that was fully stable to Fmoc-SPPS conditions and would be
easily removable under photoirradiation without damaging the
peptide backbone and other sensitive functionalities.79 In this
regard, the {7-[bis(carboxymethyl)amino]coumarin-4-yl}methyl
(BCMACM) group was introduced and successfully employed to
protect the g-carboxy group of Glu during a model reaction and the
protector was released post ligation to afford the target molecule.
2.7. Thiol auxiliary-mediated NCL
The necessity of Cys at the ligation site was a bottleneck for the
wide utility of NCL and its application for the synthesis of non-Cys
peptides was very much limited. For instance, during the synthesis
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Fig. 8. HPLC proﬁle of reactants and ligation product of human lysozyme. Inset depicts its ESI-MS (deconvoluted value: 14,693.40.7 Da; calculated value: 14,692.7 Da).
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e9537 9509of a protein, barnase, a non-critical amino acid Lys was replaced
with Cys to make the peptide segments suitable for ligation.26b As
Cys is a less-common amino acid in proteins and comprises only
1.7% of the total count, the development of methods alleviating the
need for the Cys residue has grown as an important sub-area of
research. Consequently, the use has been reported of removable
thiol auxiliaries that are attached to the N-termini of the peptide,
which perform the functions of Cys during the ligation and can be
chopped at a later stage to obtain, ultimately, the native peptides
(Scheme 27).80,81A useful auxiliary has to be introduced efﬁciently through
a simple method, should be compatible with SPPS, must facilitate
the ligation rapidly atw1mM concentration in denaturing aqueous
buffer and needs to be removed selectively under mild conditions.
The steric bulk of the auxiliary should not affect the rate of ligation.
Canne et al. developed ethanethiol and oxyethanethiol as
N-auxiliaries and demonstrated their use in the Cys-free ligation of
a few model peptides (Scheme 27).82 Ligations were carried out in
either 8 M urea/0.1 M Na2HPO4 at pH 7.0 or in 6 M Gnd$HCl/0.1 M
Na2HPO4 at pH 7.5. Appreciable yields were obtained in each study.
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removed by using Zn/Hþ.
The use of the Na-(1-phenyl-2-mercaptoethyl) group as auxiliary
was successfully demonstrated for Cys-free NCL,80 which can be re-
moved undermildly acidic conditions in a post ligation step. Amodel
peptide,Na-(Aux)GlySerTyrArgPheLeu,was ligated to few peptide-a-
thioesters including PheGlyGly, TBP-A 1-His67, Mouse Larc 1-Ala31,
and MCPI 1-Lys35 employing either Na-(1-(4-methoxyphenyl)-2-
mercaptoethyl) or Na-(1-(2,4-dimethoxyphenyl)-2-mercaptoethyl)
as the auxiliary. After ligation, the auxiliary was removed via the acid
treatment to afford a solitary yield of the target peptide (Scheme 28).Peptide-1-COS-alkyl + HS
H
N Peptide-
O
OMe R = H, Me
HF (R = H)
or TFA (R = OMe) Peptide-1 NH
O
O
P
auxiliary removal
R
Scheme 28. Na-(1-Phenyl-2-mercaptoDawson et al.81 arrived at an improved class of 2-
mercaptobenzyl-based auxiliaries, which were designed to be
more acid labile and possess improved ligation efﬁcacy by mod-
ulating the electron density. Model experiments were carried out
to demonstrate the competence of each auxiliary to ligate at dif-
ferent junctions viz., Gly/Gly, Lys/Gly, Gly/Ala and Ala/Ala. A 62-
amino acid sequence SH3 domain from a-spectrin was synthe-
sized using a trimethoxy-substituted 2-mercaptobenzyl auxiliary
(Scheme 29).
The ligation of SH3 a-spectrin[1e27] thiophenol thioester with
SH3 a-spectrin Tmb[28e62] in 6MGnd$HCl/200mMNaH2PO4 at pH2
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Scheme 29. 2-Mercaptobenzyl based auxiliaries for Cys-free NCL.
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e9537 95117.0 afforded SH3 a-spectrin 28-N-Tmb (Tmb¼4,5,6-trimethoxy-2-
mercaptobenzyl). After the removal of the auxiliary through treat-
ment of the lyophilized crude ligation product with 5% triisopro-
pylsilane in TFA for 2 h at 23 C, the end product was obtained in 66%
yield.
In an altogether different approach, Lu and Tam designed a re-
versible and reusable C-terminal mercaptoethyl ester as a thiol
handle for NCL (Scheme 30).83 Initially, the peptide mercaptoethyl
ester (thiol handle) reacts with a peptide-a-thioester through
transthioesteriﬁcation to generate an esterethioester intermediate.
Agþ activation triggers S/N acyl migration to form a peptide bond
and subsequent regeneration of the mercaptoethyl ester, which can
either be removed under mildly basic conditions or can be retained
as thiol handle for a subsequent ligation.
Wong et al. developed sugar-assisted Cys-free ligation (SAL) in
which the thiol handle inserted at the C-2 acetamido unit of a sugar
moiety attached to the peptide backboneplays the role of Cys during
ligation.84 The sulfhydryl group of the sugar unit participates in
transthioesteriﬁcation with a peptide-a-thioester under NCLH2N Peptide-1 S
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Scheme 30. C-Terminal mercaptoethyl esterconditions and S/N acyl migration occurs through a macrocyclic
intermediate (Scheme 31). An 82-amino acid antibacterial glyco-
peptideddiptericin εdpossessing two glycosylation sites at Thr10
and Thr54 was dissected into three fragments and assembled from
C- to N-terminus through SAL followed by NCL. The Gly52-Val53
sequence next to the glycosylation site Thr54 served as a suitable
junction to operate SAL. Thus, the synthesis involved SAL between
Cys(Acm)37-Gly52 andVal53-(Thr54GalNHAc)-Phe82 followedbyNCL
between the fragments Asp1-Asp36-SR and Cys37-Phe82. While
synthesizing the middle fragment (37e52), the Ala37 was mutated
with Cys for the purpose of ligation. The N-acetyl galactosamine
(GalNAc) unit attached toThr54 was equipped with a thiol handle to
facilitate SAL (Scheme 30). Thus, the ﬁrst ligation between dipter-
icin-[Cys(Acm)37-52] and diptericin-[Thr54{GalNAc(SH)}(53e82)]
in 6MGnd$HCl, 200mMphosphate (pH¼8.5) afforded Cys(Acm)37-
Phe82with36%yield in 48h. In thenext step, theAcmgrouponCys37
was removed by treatment with Hg(OAc)2/AcOH and was sub-
sequently ligated with Asp1-Asp36-SR to afford the full-length gly-
copeptide. After RP-HPLC puriﬁcation followed by lyophilization, itptide-1 S
O
eptide-2 O
O pH 5.6
Ag+
H 7.6 H2N Peptide-1 NH
O
Peptide-2 OH
O
SH polypeptide
oval of
handle
SFGGSAEVSYG; FTQGVGNPVGGYGGFLG
as reversible and reusable thiol handle.
Scheme 31. Sugar-assisted native chemical ligation.
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GalNHAc at Thr54 as well as to convert Cys37 into Ala. After ﬁnal
puriﬁcation and lyophilization, diptericin was isolated in an overall
yield of 54% (254 mg; ESI-MS analysis, found: 5408 Da; calculated
value: 5409 Da).
Brik andothers developed a side-chain-assisted ligation (SCAL) for
Cys-free NCL. In this protocol, a thiol-modiﬁed cyclohexyl auxiliary
linked to the side chain of Ser/Thr or Asp/Glu was employed to facil-
itate thiol capture from a peptide-a-thioester.85 The cyclohexyl moi-
etywas removedpost ligation throughsaponiﬁcation. TheC-terminal
50-mer fragment of HIV-I Tat protein was assembled through SCAL,
which was later attached to the remaining portion of the peptide
through NCL to obtain the full-length protein (Scheme 32). SCAL be-
tween Tat(61e86) having a cyclohexyl auxiliary at Ser62 and Thz37-
Tat(38e60) was carried out at a concentration of 2e3 mM in 6 M
Gnd$HCl, pH 8 (1:1.1 molar ratio of peptide-a-thioester to peptide
auxiliary), which took about 72 h at 37 C. In the next step, Thz wasThz Tat 38-60
37
SR
O
N
H
H
N
O
O
NHO
HS O
H2N
O
Tat 63-86 thiol
exchange
Thz
N
H
H
N
O
O
NHO
HS OH
N
O
Tat 63-86
O
Thz Tat 38-60
37
Tat 1-36
O
1. Thz--> Cys
2.
NCL
3. auxiliary re
MEPVDPRLEPWKHPGSQPKTACTNC
ISYGRKKRRQRRRAPQGSQTHQVSL
1
60
Scheme 32. Side-chain-assisteconverted into Cys by treatment with methoxylamine (37 C, 24 h),
and the intermediate peptide, after puriﬁcation,was subjected toNCL
with Tat(1e36)-COSR to afford HIV-1 Tat protein.
Several other auxiliarieswere also developed for Cys-freeNCL and
their utility has been successfully demonstrated (Fig. 9).53,77,86,87
2.8. NCL at non-Cys amino acids
Development of a Cys-free NCL protocol, to have any amino acid
(Xaa-Xaa) at the ligation site, would be practically beneﬁcial, espe-
cially when the target protein does not contain Cys, or, if so, not at the
desired position. The simplest route to have access to a non-Cys resi-
due at the ligation site is to carry out a post ligationmodiﬁcation such
as desulfurization of Cys to an Ala residue. This was ﬁrst reported by
YanandDawson.88 In theirapproach, the targetproteinwasbisectedat
theXaa-Alajunction, but the ligationwas carriedout by keepingCys at
the N-terminus in place of Ala. After ligation, the Cys residue wasN
H
H
N
O
O
NHO
S O
H2N
O
Tat 63-86
O
_Tat 38-60 SCAL
SR
moval Tat 1-36-Cys-Tat 38-60-Gly-Ser-Tat 63-86
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Fig. 9. Auxiliaries for Cys-free NCL.
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e9537 9513converted into Ala through desulfurization to obtain the native se-
quence (Scheme 33). The relative abundance of Ala in proteins makes
this protocol attractive, thus opening up plenty of options in the ret-
rosynthetic analysis of a protein todissect into the ligatable fragments.
Theutilityof such aprotocolwasdemonstrated by the synthesis of the
antibiotic, microcin J25, a 21-amino acid cyclic peptide. For the cycli-
zation via NCL, the linear peptide (17.6 mg) was dissolved in buffer
(0.1MTris$HCl, 6MGnd$HCl in thepresenceofbenzylmercaptan (2%)
and thiophenol (2%) additives at pH 8.5 (Tris¼tris(hydroxymethyl)
aminomethane hydrochloride)). The cyclized product was isolated
through semipreparative HPLC in 50% yield (7 mg; ESI-MS:
2139.60.3 Da; calculated value: 2139.4 Da). The desulfurization was
effected using Pd/Al2O3 or Raney nickel. Desulfurization employing
Pd/Al2O3 in 6 M Gnd$HCl at pH 7.5 led to the formation of trace
amounts of disulﬁde compound along with the desired microcin J25
(high-resolutionMALDI-FTMS, found:2107.0284Da; calculatedvalue:
2107.0284 Da, Fig. 10). However, when the reactionwas carried out at
pH 4.5, no dimerizationwas recorded and the reactionwas complete
in 2 h with 50% yield. Besides this, other catalysts such as Pd/C, Pd/
BaSO4 or Raney nickel also gave appreciable yields of desulfurized
product while, with PdO, the reactionwas incomplete.Cys-GHVPEYFVGIGTPISFYGGG-SR
cyclisation
through NCL Cys-GHVPEYFVGIGTPISFYGGG
desulfurization Ala-GHVPEYFVGIGTPISFYGGG
Microcin J25
SR
O
H3N
S
O
N
H
O SH
O
selective
desulfurization
of Cys
N
H
O
O
Insertion of
Ala at the ligation site
0.1 M Tris.HCl,
6.0 M Gnd.HCl
Bzl-SH (2%), PhSH (2%)
Scheme 33. NCL followed by desulfurization to establish Ala at the ligation centre.
Fig. 10. HPLC and ESI-MS spectra of microcin J25.b-Mercapto derivatives of several other amino acids were also
developed and put to use in Cys-free NCL. Subsequent de-
sulfurization afforded the corresponding amino acid at the ligation
site. Penicillamine (Pen) was selected to afford a Val residue afterdesulfurization89 and, similarly, erythro-b-mercapto-phenylala-
nine90 furnished Phe at the ligation site (Fig. 11).
An interesting addition to the non-Cys type of ligation protocols
was reported by Yang et al. and others who prepared b-mercapto
derivatives of Lys.91 The thiol handle equipped at theg-carbonof Lys is
b to both a- and ε-amino groups and participates in ligation in a tan-
demmanner for acylation of both the amines of Lys. 4-Mercaptolysine
was introduced at the N-terminus of a peptide with its ε-amine pro-
tected using a benzyloxycarbonyl (Z) group. Thus, 4-SH-Lys(Z)-
GAKAFA-NH2 was reacted with the thioester peptide, H-LSTEA-COSR,
atpH8.0and the reactionwas found toproceed to completion inabout
an hour with a yield of over 90%. To facilitate ligation at the ε-amine,
the Z group was removed and the peptide segment was treated with
H-LSTEG-COSR to afford the desired product in 1.5 h in 92% yield.
Desulfurizationwas effected in 6M guanidine, 0.2M phosphate at pH
6.0, employing 100 mM tris(2-carboxyethyl)phosphine (TCEP) to re-
instate the unmodiﬁed Lys at the ligation site (Scheme 34).
A list of various b-mercapto derivatives available for non-Cys NCL
and the corresponding amino acids obtained after desulfurization
alongwith the reaction conditions and yield are delineated inTable 3.
A straightforward and high yielding synthesis of g-(R,S)-mercapto-glutamine was reported by Brik et al.92 The study demonstrated the
utility of g-(R,S)-mercaptoglutamine in the synthesis ofWWdomain
(1e40) derived from YAP65 WW domain polypeptide.92 The de-
sulfurization was carried out using nickel boride.88
HS Ph
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Fig. 11. b-Mercapto derivatives for Cys-free ligation (selected examples).
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Scheme 34. 4-Mercaptolysine mediated NCL.
Table 3
Few mercaptoamino acids used in Cys-free NCL and their desulfurization condition (selected examples)
No. b-Mercapto derivative Amino acid obtained after desulfurization Desulfurization conditions Yield (%) Ref.
1 Cys Ala Pd/Al2O3 90 88
2 Pen Val VA-044,a TCEP, EtSH 98 89
3 erythro-b-Mercapto-Phe Phe NiCl4$6H2O, NaBH4 80 90
4 (2S,4S)-4-Mercapto-L-Lys Lys VA-044,a TCEP 40 91a
a VA-044¼2,20-azobis[2-(2-imidazolin-2-yl)propane]dihydrochloride.
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e95379514Interestingly, a simple route involving free-radical-based, mild,
highly versatile and speciﬁc desulfurization of Cys to Ala based on
classical organic chemistry (Scheme 35) was developed byWan and
Danishefsky.93a The reaction was carried out using (tBUSH), tris(2-
carboxyethyl)phosphine (TCEP, phosphine source), 2,20-azobis[2-
(2-imidazolin-2yl)propane]dihydrochloride (VA-044, radical initi-
ator) in water at room temperature for about several hours. This
reaction takes place without side reactions. Additional studies in
this direction were carried out by Haase and Seitz also.93b This
metal-free reduction of Cys is tolerant to a range of relevant func-
tional groups. The advantages of this method have been demon-
strated by the synthesis of glycooligopeptides93a and human
parathyroid hormone (hPTH, 84 residues).93cRSH P(OEt)3 RH SP(OEt)3
hv
P(OEt)3 RS-P(OEt)3 R SP(OEt)3
R RSH RH
RS
RS
Scheme 35. Proposed mechanism of radical desulfurization reaction.Tam and Yu developed a viable chemistry to establish Xaa-Met
as the ligation site. This protocol consisted of a ligation between
an N-terminal homocysteinyl peptide and a peptide-a-thioester
followed by S-methylation to convert homocysteine (Hcy) into
a Met residue (Scheme 36).94 The ligation was performed at pH 7.6
in phosphate buffer in a highly reductive environment and was
generally complete in about 4 h. Selective methylation was carried
out employing an excess of methyl p-nitrobenzenesulfonate. Inamodel study, a peptide, KLYG-SCH2CH2CONH2, was ligated to Hcy-
ARVELKKLQDV and then methylated to obtain the product in 73%
yield. Its efﬁcacy was further conﬁrmed through the synthesis of
a 34-amino acid human parathyroid hormone fragment, SF34
(SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF). The strategy
was also found to be useful for the preparation of cyclic peptides
employing unprotected homocysteinyl peptide-a-thioesters.94
Raines and others demonstrated selenocysteine (Sec)-mediated
NCL.95 A model reaction between Ac-Gly-SR and selenocysteine
[(Sec)2] gave the corresponding ligated product (Ac-Gly-Sec-OH)2.
The RSe is more nucleophilic compared to RS and the pKa of
a selenol is much less than its thio analogue. Hence, the ligation
reaction carried out employing Sec was 103-fold faster than that
with Cys, especially at low pH (Scheme 37). To demonstrate the vi-
ability of Sec-mediatedNCL, ribonuclease A (RNase A)was chosen as
amodel. Out of the eight Cys residues present in themolecule, Cys110
was replaced with Sec and the ligation between RNase A (1e109)
with RNase A (Sec110-124) was carried out at pH 8.0 in 0.10 M
Tris$HCl buffer containing tris-(2-carboxyethyl)phosphine (TCEP).
In a similar manner to Sec-mediated NCL, Roelfes and Hilvert
developed a route for the insertion of selenomethionine (SeMet) at
the ligation site.96 The ligation was performed between a peptide
with N-terminal selenohomocysteine (SeHcy) and a peptide-a-
thioester. After the ligation, the selenol was methylated to install
SeMet at the ligated junction. A model reaction was carried out
between a peptide, LYRAG-Set, with SeHcy (1 mM in Tris$HCl
buffer, pH 8.5, 6MGnd$HCl, 5% thiophenol), whichwas complete in
20 h. The reaction afforded the product as a diselenide, which was
methylated using methyl 4-nitrobenzenesulfonate under reducing
conditions (excess thiophenol) to obtain 4.0 mg of the SeMet-
containing peptide in 66% yield (Scheme 38). The utility and efﬁ-
cacy of the method were demonstrated by synthesizing seleno bPP,
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O
SR + H2N
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O
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1. thioester
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2. S,N-acyl
migration
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O
N
H
S
O
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Scheme 36. Homocysteine mediated NCL followed by thiol methylation establishes Met at the ligation junction.
Scheme 37. Selenocysteine mediated NCL.
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Scheme 38. Selenohomocysteine mediated NCL followed by methylation establishes SeMet at the ligation junction.
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e9537 9515a variant of bovine pancreatic polypeptide containing SeMet at
positions 17 and 30. This 36-amino acid polypeptide is a member of
the neuropeptide Y family and plays a vital role in the regulation of
food uptake. The fragments were assembled on solid phase
employing Fmoc/HBTUeHOBt chemistry. The ligation was carried
out in excess thiophenol in a buffer (Tris$HCl and Gnd$HCl). The
reaction was sluggish and was driven to completion after 5 days by
the addition of a fourfold excess of thioester. The crude product
containing the diselenide and a mixed selenosulﬁde withthiophenol was methylated by treatment with Tris$HCl (1 equiv) in
sodium phosphate buffer (200 mM, pH 6.0) in the presence of
methyl 4-nitrobenzenesulfonate (5 equiv). The crude product was
puriﬁed using RP-HPLC to afford 6.8 mg of seleno bPP.
2.9. Salicylaldehyde ester-induced ligation
Li et al. introduced a different concept for Cys-free chemo-
selective ligation in which a Ser/Thr can be incorporated at the
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e95379516ligation junction. A reaction between a peptide bearing a C-ter-
minal O-salicylaldehyde ester with a peptide having an N-terminal
Ser/Thr was carried out.97 The ﬁrst step involves a reversible re-
action of the a-amino group of Ser/Thr with the aldehyde to form
an imine followed by an intramolecular cyclization to an oxazoline
ring. Further, O/N acyl transfer affords a stable acetal in-
termediate, which on acidic treatment establishes the peptide bond
with concomitant removal of the auxiliary (Scheme 39). NCL at
other sites such as pseudocysteine has also been demonstrated, but
these methods are yet to gain general applicability.98Peptide-1 O
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Scheme 39. N-Terminal Ser/Thr ligate chemoselectively to peptides bearing C-terminal salicyladehyde ester.2.10. Ligation mediated by quinolinium thioester salts
A novel approach, which relies on conjugated addition to qui-
nolinium salts that aid amine capture and result in the establish-
ment of a peptide bondwas developed by Levacher. In this reaction,
two steps, namely the acyl transfer and removal of the template,
take place simultaneously.32 The method involves the reaction
between a peptide-a-thioester equipped with a quinoline template
and the amino terminus of a peptide fragment. The entropic acti-
vation of the peptide-a-thioester substrate is achieved via N-
methylation of quinoline using methoxytriﬂate (MeOTf) that de-
velops an electrophilic platform and thus attracts the amine ter-
minus of the peptide. Acyl migration and consequent detachment
of the quinoline moiety lead to the insertion of a peptide bond
(Scheme 40).
2.11. NCL through peptide phenyl esters
The success of NCL can be attributed to the rate of the thio-
transesteriﬁcation step, i.e., S/S acyl transfer, which in turn depends
on the steric bulk of the amino acid at the thioester termini.Danishefsky et al. envisaged that replacement of S/S acyl transfer
with the more favourable O/S acyl transfer would be advanta-
geous.29This ideacoinedtheterm,oxoester-mediatedNCL,whichwas
demonstrated through the ligation of a model p-nitrophenyl ester of
an Fmoc-peptide with an N-terminal Cys-peptide (Scheme 41).
Interestingly, the oxoester-mediated ligation proceeded
smoothly with a series of peptides having hindered C-terminal
amino acids including Thr, Val, Ile, D-allo-Ile and Pro, while race-
mization of up to 5e6% was recorded when Leu, Ile and Val were
present at the C-terminus.2.12. Synthesis of glycopeptides
Protein glycosylation is known to effect protein folding and play
a speciﬁc role in improving the in vivo half life. Asmuch as 40% of the
proteins are glycosylated.99 Despite their signiﬁcance, much ad-
vancement in understanding the structureefunction of glycopro-
teins has been retarded, due to the difﬁculties associated with their
isolation in chemically homogeneous forms to both from natural
sources as well as from preparation through chemical methods.
Although an ultimate and highly convergent protocol would be to
merge a matured oligosaccharide unit into a polypeptide domain,
the protocol would face solubility, selectivity and other practical
considerations. It would be better if an oligosaccharide is ﬁrst cou-
pled to a more manageable short peptide and then ligated to
a polypeptide or protein fragment. Approaches to obtain diverse
types of glycopeptides and glycoproteins have been reviewed pre-
viously.100 NCL is one of the latest techniques to be adopted for the
assembly of these important classes of biomolecules.101
Bertozzi’s group assembled an 82-amino acid residue glyco-
protein, diptericin, employing NCL.54 Diptericin consists of an N-
terminal Pro rich domain (1e20) and a C-terminal Gly rich domain
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H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e9537 9517(26e82) bridged by ﬁve Gly residues in series. The lack of Cys in the
sequence is a technical hurdle for its assembly through NCL. Hence,
Gly25 was replaced with Cys to make this protein suitable for NCL.
Further, to ease the synthesis, two more modiﬁcations were
madedAsp29 and Asp45 were replaced with Gludand all these
substitutions were assured not to affect the native biological and
structural properties. The sugar unit, Gln(NHAc), was equipped at
two positionsdThr10 and Thr54dby incorporating the O-glycosy-
lated-Thr during the chain assembly. Thus, the two glycopeptide
segments selected for ligation were: glycopeptide-a-thioester
Thr10(Ac3-a-D-GalNHAc)diptericin(1e24)-COSBn and N-Cys-glyco-
peptide Cys25-[Thr54(Ac3-a-D-GalNHAc)]diptericin(25e82). The
thioester fragment was synthesized on solid phase using Kenner’s
modiﬁed sulfonamide linker as described previously (Section 2.2;
see also Scheme 11). The Cys-peptide fragment was assembled on
a Rink resin by SPPS and characterized. The peptide-a-thioester,
Thr10-diptericin(1e24)-COSBn (1.4 mg, 0.5 mmol), was ligated with
Cys25-diptericin(25e82) (5.0 mg, 0.75 mmol) in 6 M Gnd$HCl, 0.1 M
sodium phosphate (pH 7.5) and 4% thiophenol (Scheme 42). The
reaction was complete after 18 h, as monitored by HPLC. The
product was isolated through preparative HPLC in 55% yield
(2.6 mg). Removal of the acetate protections on the sugars by
treatment with 5% aqueous hydrazine afforded 1.33 mg of the
protein (yield: 53%), which was characterized by ESI-MS (observed:
9172 Da; calculated: 9171.99 Da).
Danishefsky et al. accomplished the assembly of N-linked gly-
coproteins through NCL.102a Starting with the unprotected saccha-
rides, the anomeric carbon was aminated under a Kochetkov
reaction using NH4HCO3.102b In the next step, the glycosylated
amines were acylated to the b-COOH group of the Asp residue in
the N-protected-Cys-pentapeptide pre-activated with 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyr-
idinium hexaﬂuorophosphate 3-oxide (HATU) in the presence of
a tertiary base. In parallel, a tetradecapeptide thioester was as-
sembled on poly(ethylene)glycol (PEG)-supported Wang resin
employing Fmoc/tert-Bu/SPPS. A ligation of the polypeptide-a-
thioester with a Cys-glycopeptide fragment was carried out on
a 15mg scale in phosphate-buffered saline (PBS, 0.2M), at pH 7.4, in
the presence of excess sulfanylethane-2-sulfamate. After the liga-
tion, a global disulﬁde reduction using water soluble TCEP afforded
the fully unprotected glycopeptide in 78% yield (Scheme 43).
Boons et al. demonstrated a liposome mediated NCL to assemble
sparingly soluble lipopeptides.103 A model lipoglycopeptide was as-
sembled through the condensation of three componentsda tumour
associated glycopeptide derived from mucin-1 (protein targeted in
cancerous cells; MUC-1), a known T-cell epitope, YAFKYAR-
HANVGRNAFELFL, and a lipopeptide, S-[(R)-2,3-dipalmitoyloxy-pro-
pyl]-N-palmitoyl-(R)-cysteine (Pam3CysSK4). Initially, the MUC-1
epitope was assembled on solid phase employing Fmoc-amino
acids [Thr was introduced as Fmoc-Thr-(a-AcO3-D-GalNHAc)-OH] on
Rink amide resin. After cleaving from the solid support (TFA: 94%,
water: 2.5%; ethanedithiol: 2.5% and TIS: 1%), the peptidewas treated
with 5% hydrazine to deprotect the acetyl groups on galactose. The
other two fragments were assembled on solid phase employing
a sulfonamide safety-catch linker. In the next stage, MUC-1 and T-cell
epitope were ligated under standard conditions (6 M Gnd$HCl,
200 mM NaHPO4, 4% thiophenol), and this was complete in 18 h, as
monitored by LCeMS. The product was isolated through semi pre-
parative RP-HPLC in 48% yield. In the following steps, the Acm pro-
tector on the N-terminal Cys was removed using Hg(II)OAc and the
free amino glycopeptide was subjected to ligation with the lip-
opeptide, Pam3CysSK4. Under standard conditions, the ligation did
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Scheme 43. Utility of NCL in assembling glycopeptides.
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improve the solubility by adding detergents or through higher tem-
peratures met with limited success. To facilitate the solubilization of
the two ligating fragments, the assistance of liposomeswas explored.
A ﬁlm of dodecylphosphocholine, glycopeptides and lipopeptide
thioester was hydrated by incubation at 37 C for 4 h in a phosphate
buffer (pH 7.5) in the presence of carboxyethylphosphine and ethyl-
enediaminetetraacetic acid (EDTA). The latter tworeagentswereused
to suppress disulﬁde formation. The mixture was ultrasonicated for
1minand theresultingvesicleswere sized to1mmbypassing through
a polycarbonate membrane ﬁlter. The ligation was catalyzed by the
addition of sodium 2-mercaptoethanesulfonate. The reaction was
complete in 2 h and the target lipoglycopeptide was isolated in
83% yield (3.5 mg) after HPLC isolation, which was conﬁrmed
through MALDI-TOF (observed: 5392.9712 Da; calculated value:
5392.0171 Da; Scheme 44).
Danishefsky visualized that a peptide phenolic ester equipped
with a thiol moiety at the ortho position can be ligated to anN-terminal Cys-peptide.104 Thus, an ester possessing an adjacent
thiol group present in equilibrium with a thioester participates in
NCL with a Cys-peptide. Commercially available 2-mercaptophenol
was oxidized to its symmetrical disulﬁde, from which the un-
symmetrical alkyl aryl disulﬁde was prepared by treating with
excess diethyl sulﬁde. The resulting phenol was esteriﬁed to Boc-
Phe-OH and the Boc group was cleaved by treatment with TFA. It
was then coupled to a protected peptide acid under standard
coupling conditions using O-(7-azabenzotriazolyl)-1,1,3,3-
tetramethyluronium hexaﬂuorophosphate (HATU) followed by
glycosylation of the aspartyl residue of the peptide with a chito-
biose-derived glycosylamine to afford the glycopeptide phenyl es-
ter. Then, the Cys-glycopeptide (1.44 mmol) assembled on solid
phase was ligated to the glycopeptide phenyl ester (1.44 mmol)
employing strongly reducing conditions [0.2 M phosphate, 0.2 M
NaCl and excess sodium 2-mercaptoethanesulfonate, (MES-Na)],
under which, the protector on Cys and the phenyl ester were re-
leased along with subsequent NCL to afford the corresponding
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H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e9537 9519glycopeptide (Scheme 45). No racemization was observed and the
product was conﬁrmed through ESI-MS (calculated: 1108.5 Da;
observed: 1108.6 Da) and 1H NMR techniques.
2.13. Combination of NCL with click chemistry
Brimble et al. reported the synthesis of glycopeptidomimetics by
combiningNCLwithCu(I) catalyzed azideealkyne cycloaddition.105a
The click reaction is employed for the regioselective synthesis of 1,4-
substituted 1,2,3-triazoles. A one-pot protocol was developed in
which a peptide-a-thioester and a Cys-peptide, both equipped with
an alkyne functionality, were ligated under normal conditions fol-
lowed by a click reaction with an azidosugar to afford the triazole-
linked glycopeptidomimetics. Boc-L-propargylglycine (Boc-L-Pra-
OH)was prepared and inserted into bothpeptide-a-thioester andN-
Cys-peptide during the fragment assembly to have a ‘clickable’
centre. A 3-mM quantity of each segment was dissolved in 6 M
Gnd$HCl/0.2 M Na2HPO4 along with TCEP and mercaptophenyl-
acetic acid (MPAA; pH 7.0). After the completion of ligation, the click
reaction was initiated by adding CuSO4 (20 mM) followed by Gal-
NAc-N3 (10 mM). The reaction was complete after 6 h (Scheme 46),
and the resulting 23-residue neoglycopeptide containing two tri-
azole units was isolated, which had a mass of 3252.0 Da0.4 Da in
agreement with the theoretical value (3252.6 Da).
Xiao and Tolbert also employed a click reaction in combination
with NCL to assemble N-terminally linked protein dimers and
trimers.105b
Diversity inboth themethodologyofprotein ligationanddesignof
molecules is being brought about by carrying out the ligation at lipid
interfaces.106 NCL has been applied to the syntheses of polymers,
hydrogels, lipopeptides, glycolipopeptides, protein helical bundles
and cyclic peptides, and for protein ubiquitination.107,108 It is likely
thatNCLwould enjoy a still wider utility in chemical biologywith the
underpinning of the recent developments such as automation of
SPPS, easy access to synthetic peptide-a-thioesters and successful
removalof thenecessityofhaving the less-commonCys residueat the
ligation site.Asandwhen itbecomespossible toengineermuch largerfragments, the NCL will be at its peak as a tool to mimic nature with
respect to protein synthesis. Progress in the ﬁeld of chemical as-
sembly of polypeptides and proteins has always followed advances in
the strategy for preparation of polypeptide-a-thioesters and ligation
techniques. Both strands of research have come together with the
development of expressed protein ligation (EPL), which has opened
up new avenues for the assembly of large proteins.
3. Expressed protein ligation
EPL,109,110 oneof themilestones in ligation techniques, haswidely
expanded the scope of NCL. The chemical syntheses of peptide
fragments required for NCL is even now a technically demanding
process with size constraints. Consequently, the utility of NCL has
centred around the assembly of proteins only in the range of 15 kDa.
EPL is a biosynthetic version of NCL where a protein thioester gen-
erated recombinantly by the thiolysis of an intein fusion protein is
ligated to a semisynthetic or recombinant protein with N-terminal
Cys to produce a native protein. This technique, also known as
intein-mediated protein ligation (IPL), has found applications in the
synthesis of peptide C-terminal thioesters as well as oligopeptide
fragmentswithN-terminalCys. Thequestionof howtoobtaina large
protein fragment required for ligation leads to an interesting bi-
ological processdprotein splicing.111 This is a post-translational
process in which a precursor protein undergoes a series of intra-
molecular rearrangements, resulting in the precise excision of an
internal region referred to as intein and ligation of the two lateral
sequences (exteins).
The ﬁrst step in protein splicing (PS) involves an N/S (or N/O)
acyl shift in which the N-extein unit is transferred to the thiol (or
hydroxy) group of a Cys (or Ser/Thr) located at the immediate N-
terminus of the protein. Although this step is apparently thermo-
dynamically unfavourable, the structure of the intein is supposed to
catalyze it through twisting the scissile amide bond into a higher
energy conformation thereby guiding the equilibrium to the thio-
ester (ester) side. Then, the entire unit is shifted to a secondCys (Ser/
Thr) residue at the intein/C-extein boundary (þ1 position) in
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H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e95379520a transesteriﬁcation step. The branched intermediate, in the next
step, undergoes a cyclization reaction involving a conserved Asn
residue at theC-terminusof the intein,whichwill be removedas aC-
terminal succinimidederivative. Finally, an S/N (orO/N) acyl shift
establishes the amide bond between the two exteins (Scheme 47).
Suitable engineering has been developed in protein splicing to
generate protein-a-thioesters.112 Commercially available pCyB
vectors for E. coli protein expression can be employed to generate
an a-thioester in which a protein of interest is expressed in a frame
fused with an inteinechitin binding domain (CBD) sequence. Thi-
olysis of the intein fusion protein using 2-mercaptoethanol or
dithiothreitol (DTT) yields the protein-a-thioester through trans-
esteriﬁcation (Scheme 48). This highly reactive protein-a-thioester
can be ligated instantaneously with an N-Cys-peptide to afford theproduct. Instead, if the thiolysis is carried out with ethyl thiol, less
reactive peptide alkyl thioesters are obtained, which can be iso-
lated. The chemistry was fully established to generate N-Cys pro-
teins as well through recombinant synthesis. EPL has been applied
to the synthesis of several classes of proteins from both prokaryotic
and eukaryotic organisms.113 Over 40 different proteins are
addressed with EPL including kinases, phosphatases, transcription
factors, polymerases, ion channels, cytoplasmic signalling proteins,
histones and antibodies.114,115
3.1. Case studies
Wang and Cole demonstrated the use of intein fusion constructs
as a source of large recombinant protein-a-thioesters in the
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H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e9537 9521synthesis of a pair of semisynthetic C-terminal Src Kinase (Csk),
a 50 kDa protein.116 This opened up a new era to access large pro-
teins that are otherwise difﬁcult to obtain through chemical syn-
thesis. Csk catalyzes the phosphorylation of a highly conserved
tyrosinewithin the C-terminal tails of Src family members. To study
the potential effect of attachment of a phosphotyrosine tail to Csk,
its synthesis through EPL was undertaken. Csk protein was
recombinantly expressed in E. coli as the corresponding thioester.
To ligate with this, tyrosine phosphorylated and unphosphorylated
forms of the peptide, NH2-Cys-Asp-Asn-Glu-Tyr-Thr-Ala-Arg-Glu-
aminocaprase-Lys-ε-[ﬂorescence]-COOH, were synthesized and, in
the last step, the recombinant protein-a-thioester and synthetic
peptides were ligated at pH 7.0 in the presence of 2% thiophenol.
Bacterial potassium channel (KcsA) is a protein possessing 160
amino acids. Its truncated form corresponding to the ﬁrst 125
amino acids was synthesized via EPL by Muir through a two frag-
ment ligation of KcsA[1e73] with KcsA[74e125].117 To facilitate its
assembly through NCL, Thr74 was replaced with Cys and this re-
placement was conﬁrmed to be unaffected by the properties of the
protein. A bacterial expression strategy was used to generate the N-
peptide-a-thioester fragment {KcsA[1e73]}. The recombinant
proteins were directly converted into a-thioesters through thiolysis
of intein fusion protein. The KcsA[74e125] segment was synthe-
sized using Boc/HBTU-SPPS. The best ligation results between these
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e95379522two fragments were obtained at pH 7.6 using 50% polytetra-
ﬂuoroethylene (PTFE), 1% sodium dodecyl sulfate (SDS) and 2%
thiophenol (Scheme 49).Scheme 49. Application of EPL in assembling KcsA fragment.Ligationwas complete in 2 h at 37 C and the ESI-MS data of the
puriﬁed product were found to be 13,634.84.4 Da, in agreement
with the calculated value (13,633 Da). The folding reaction was
carried out concomitantly in the same ﬂask employing lipid buffer
(100mMTris, pH 7.5, 200mMNaCl,15mMKCl,10% glycerol, 10mM
DTT).
4. Traceless Staudinger ligation
A recently developed technique for joining two largepolypeptide
fragments is Staudinger ligation.31 This originates from the classical
Staudinger reaction in which an azide and a phosphinothioester
react to form an amide.27 The reaction was successfully applied asPeptide-1 SR
O
PR2
SH
Peptide 1
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Peptide-1
O
N
PR2
S
Peptide-2 hydrolysisacyl migration
Scheme 50. Working principle ofthe basis for a ligation technique by the groups of Bertozzi and
Rains.118,119 In the original Staudinger reaction, the products
retained the phosphine moiety. However, suitable modiﬁcationshave now been engineered to ensure that the product is free from
any residual components and, hence, it is aptly named as ‘traceless
Staudinger ligation’. Similarly to NCL, one of the coupling partners is
a peptide-a-thioester. Theﬁrst stepwould be transthioesteriﬁcation
of a peptide-a-thioester with a phosphinothiol, which then reacts
with thealkyl azide terminusof anotherpeptide fragment to forman
iminophosphorane intermediate. The iminophosphorane nitrogen
attacks the thioester carbonyl to yield an amidophosphonium salt,
which on PeN bond hydrolysis affords an amide bond along with
a phosphine oxide as co-product (Scheme 50).
Since its discovery, several studies have been devoted to un-
derstanding the mechanistic and methodological aspects of trace-
less Staudinger ligation, the development of water soluble2
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H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e9537 9523phosphinothiols, application to site-speciﬁc immobilization of
peptides on surfaces, such as amine-derivatized glass slides, and
utility to obtain glycopeptide and glycoconjugate systems.1204.1. Case studies
Staudinger ligation, initially, was demonstrated using glycyl
azides. Rains et al. reported Staudinger ligation at non-glycyl azides
Phe, Asp and Ser as well and further determined that the ligation
was racemization free.119 Several pairs of enantiomeric dipeptides
such as Ac-Gly-L-Phe-NHBn and Ac-Gly-D-Phe-NHBn, or Ac-Gly-L-
Asp(OMe)-NHBn and Ac-Gly-D-Asp(OMe)-NHBn were made
employing Staudinger ligation and were found to be optically ho-
mogeneous. Staudinger ligation was adopted to assemble ribonu-
clease A (RNAse A) through the condensation of three segments,
viz., RNAse A(1e109), RNAse A(110e111) and RNAse A(112e124).121
The RNAse A(1e109) fragment was expressed through a recombi-
nant technique as a C-terminal thioester. The RNAse A(110e111)
fragment was synthesized as a C-terminal phosphinothioester
(Fmoc-Cys(Trt)Glu(OtBu)SCH2PPh2) using a sulfonamide linker and
isolated in 64% yield. The third fragment, RNAse A(112e124), was
synthesized as an N-terminal azide, for which the RNAse
A(113e124) fragment [(n1)peptide] was assembled via the Fmoc-
HATU chemistry on a polyethylene glycol (PEG) resin followed by
capping with N3-CH2-COOH (residue 112) to afford N3CH2CO-
Asn(Trt)ProTyr(tBu)ValProValHis(Trt)-PheAsp(OtBu)Ala-Ser(tBu)
Val. Staudinger ligation was employed to ligate RNAse A(110e111)
with RNAse A(112e124) directly on the poly[acryloyl-
bis(aminopropyl)polyethylene glycol] (PEGA) resin. After the liga-
tion, cleavage of the peptide from the acyl resin, deprotection and
puriﬁcation afforded RNAse A(110e124). In the ﬁnal synthetic step,
this fragment was coupled to RNAse A(1e109)-a-thioester through
NCL to obtain the product (Scheme 51).
Lee et al. developed a novel core shell resin-supported phosphi-
nothiol for solid phase Staudinger ligation of peptides and also
demonstrated that the resin-boundphosphonothiol canbe reused.122Scheme 51. Staudinger ligation employed dAfter detachment of the peptide from the resin, the resulting resin-
bound phosphine oxide was recovered through ﬁltration and
reduced to the original form using trichlorosilane (Scheme 52).
Raines et al. described a water-soluble phosphinothiol for
traceless Staudinger ligation. The basic phosphinothiol, bis(p-
dimethylaminoethyl)phenyl phosphinomethanethiol (Fig. 12) was
prepared and its efﬁcacy was demonstrated through the synthesis
of peptides.123
The traceless Staudinger ligation has also been explored for
synthesizing cyclic proteins and peptides. In one such example,
borane-protected phosphinothiol was employed to install the re-
active azide and phosphine moieties in the same molecule.124 After
the removal of borane and other protecting groups, the peptidewas
subjected to ligation in the presence of 1,4-diazabicyclo[2.2.2]oc-
tane (DABCO) or diisopropylethylamine (DIPEA) (Scheme 53). In
another interesting report, traceless Staudinger ligation was
employed to preparemedium-sized lactams from peptides made of
a- and b-amino acids.1255. O-Acyl isopeptide method (click or switch peptides)
A major obstacle for the assembly of large peptides is their ag-
gregation tendency that makes coupling and deprotection re-
actions incomplete and, consequently, their puriﬁcation, extremely
difﬁcult. The synthesis of such ‘difﬁcult-sequence’ peptides has
been the subject of much attention.126,127 The inter- and the intra-
chain interactions, hydrophobic nature, and extensive hydrogen
bonding in the molecular matrix extend the secondary structure of
the peptide and thus the sequence elongation becomes sturdy. Due
to the uncontrollable folding of peptide fragments during their
synthesis, a signiﬁcant proportion of Na-amino groups becomes
inaccessible for acylation as well as deprotection. Hence, in-
complete segments (truncated and deleted sequence) emerge after
cleavage from the resin as major byproducts. To disrupt such dis-
favourable aggregation in a growing peptide, the hydrophobic in-
teractions must be kept at bay. Current strategies to prevent suchuring the synthesis of ribonuclease A.
N
H
O
P
SH
N
H
O
P
S Xaa1-Xaa2-Fmoc
O
N3
R
O
OH
N
H
O
P
S Xaa1-Xaa2-Fmoc
O
NR
O OH
Fmoc-Xaa2-Xaa1-
N
H
O
P
SH
O
reduction
hyd
roly
sis
HN COOH
R
Scheme 52. Reusable resin-bound phosphinothiol employed in Staudinger ligation.
PH
SH
Cl
HN NHCl Cl
Fig. 12. A water-soluble phosphinothiol.
N3 N
H
O
Peptide
Pg
OH
O
HS PPh2
BH3
N3 N
H
O
Peptide
Pg
S
O
PPh2
BH3
global
deprotection
N3 N
H
O
Peptide S
O
PHPh2
DABCO
Peptide
HN O
O
Peptides used: GAGHVPEYFVG; yield: 36 %
GGIVPQFYSAG; yield: 31 %
GIGTPISFYGG; yield: 20 %
THF
water,
70 oC
Scheme 53. Cyclic peptides via intramolecular Staudinger ligation.
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e95379524difﬁculties have aimed at interfering with secondary structure
properties by introducing speciﬁc reversible modiﬁcations at the
peptide backbone using: (a) pseudoproline building blocks128 and
(b) auxiliaries such as a 2-hydroxy-4-methoxybenzyl (Hmb) moi-
ety.129 In the latter method, the auxiliaries disrupt the secondary
structure formed by the inter/intra-chain interactions and facilitate
N-acylation of the secondary amine. This is carried out through acyl
capture of the activated amino or peptide acid employing the 2-
hydroxy moiety of the auxiliary via a base-catalyzed reaction fol-
lowed by an O/N intramolecular acyl transfer. The imposed C- and
N-terminal proximity drives this reaction. The foundation for such
a type of technique was laid by Brenner et al. more than 60 years
ago.130 Recently, Miranda et al. reported the use of a 2-hydroxy-6-
nitrobenzyl auxiliary with the intention of improving the efﬁciency
and yield of peptide synthesis including the couplings involving
sterically hindered amino acids.131 Initially, through reductive al-
kylation, the auxiliary is attached to a resin-bound peptide. Thehydroxy group is acylated with an Fmoc-amino/peptide acid
through HBTU activation. The O/N acyl migration leads to in-
sertion of the amide bond (Scheme 54).
Kiso et al., during their studies on the anticancer prodrugs
paclitaxel and docetaxel, found that the presence of an O-acyl in-
stead of an N-acyl moiety increased the solubility of the in-
termediate. This facilitated the convenient assembly of the
depsipeptide sequences, which in the ﬁnal stage were subjected toO/N intramolecular acyl migration to afford the unmodiﬁed target
molecule.132,133 These results were supported by the observations
of Fujii et al. who also demonstrated the synthesis of a peptidomi-
metic containing a hydroxyethyl amine dipeptide isostere through
O/N acylmigration (Scheme 55).134 The O/N acylmigrationmost
likely takes place through the formation of ﬁve-membered cyclic
transition state in case of ligations involving O-acyl Ser/Thr resi-
dues. However, Katritzky et al. have carried out ligation from O-acyl
serine sites inwhich O/N acyl migration takes place via 8- and 11-
membered cyclic transition states.135a The method involves no us-
age of cysteine or an auxiliary group at the ligation site and causes
the shift to one or two amino acid residues away from the O-acyl
serine site.
Kartritzky’s group had also demonstrated the synthesis of cys-
teine containing native peptides employing S-acyl cysteine sites
and obtaining S/N acyl shift involving 5-, 11- and 14-membered
cyclic transition states.135b
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H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e9537 9525The above two observations triggered a new technique for the
assembly of difﬁcult peptide sequences. An interesting discovery of
the quick, easy and irreversible transformation of O-acyl isopeptide
into native peptide was appropriately termed as ‘click peptide’
method by Kiso136 and as ‘switch peptide’ by Mutter and others.137
The primary requirement is the presence of a b-hydroxy amino
component. Proteinogenic amino acids Ser, Thr and unnatural
amino acid, phenylnorstatine {(2R,3S)-3-amino-2-hydroxy-4-
phenylbutanoic acid (Pns)}, provide the basic requirement. In
a growing peptide on solid phase, an ester bond is installed between
the amino acid and a b-hydroxy amino acid such as Ser/Thr and
further peptide chain elongation is continued in a regular fashion.
After the complete assembly of the desired sequence of amino acids,
the peptide is cleaved from the resin, and the protector on Ser/Thr is
released to obtain theO-acyl isopeptide (click peptide),whichunder
physiological conditions (pH 7.4) in PBS at room temperature un-
dergoes O/N intramolecular acyl migration to afford the ﬁnal
product.138 The presence of one single depsi bond [eOeC(]O)e] in
place of an amide in the sequence alleviates the unfavourable sec-
ondary structural foldings that otherwisewould lead to aggregation.
The technique can be well understood by considering the syn-
thesis of a pentapeptide, Ac-ValValPnsValVal-NH2, as demonstrated
by Kiso.139 The synthesis of the pentapeptide by the conventional
route leads to several byproducts and the solubility problems as-
sociated with this peptide posed difﬁculty during preparative HPLC
puriﬁcation as well, resulting in a very poor yield (6.9%). However,
when it was assembled via the O-acyl isopeptide method, a satis-
factory yield was obtained (18.5 mg, 57.6%, Scheme 56).FmocHN HNVal-Val
O
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BocNH
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NH2Val-Val
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TFA NH2
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Scheme 56. O-Acyl isopeptide method forDuring the click approach, Boc-Pns-OH was coupled to the
resin-bound Val-Val-NH2 and subsequent couplings onto the
b-hydroxy group of the Boc-Pns were performed using Fmoc
chemistry. After assembling the desired sequence, the Fmoc group
was cleaved and the free amino group was acetylated. After
cleavage from the resin, the Boc protector was released to afford the
click peptide. Compared to the native peptide, the ‘click peptide’
was highly water soluble (nearly 500 fold) and was therefore ob-
tained in a homogeneous form using preparative HPLC. It was
storable at 4 C for 1 month without degradation. Up on stirring in
PBS at pH 7.4, at a concentration of 1 mg/ml, the isopeptide un-
derwent rapid acyl migration (<5 min) to afford the desired
product quantitatively as a white amorphous solid.
Some advantages of the click method are:
1. the isopeptides are water soluble due to the protonated amino
group and therefore can be puriﬁed easily.
2. stable in neutral or slightly basic conditions or as a solution in
DMSO or as a solid obtainable after lyophilization.
3. the pH-triggered O-acyl migration is fast and quantitative, and
yields the product in a short duration of time.
4. the presence of a depsipeptide bond helps the peptide se-
quence to retain a monomeric form and prevents undesired
aggregation and ﬁbril formation.
5. the deprotection and coupling efﬁcacy are also enhanced in
SPPS due to the presence of the O-acyl isopeptide unit.HNVal-Val
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the synthesis of ‘difﬁcult sequences’.
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e95379526Carpino et al. demonstrated the advantage of havinganester bond
in a peptide sequence for an efﬁcient chain assembly. They chose an
extremely difﬁcult peptideda 37-residue WW domain FBP28 (per-
oxisome proliferator-activated receptor-binding protein)dwhich
exhibits a triple-stranded antiparallel b-sheet structure (Fig. 13).140GATAVSEWTEYKTANGKTYYYNNRTLESTWEKPQELK-NH2
17 27
N,O-acyl migration
1 37
TWEKPQELK-NH2
O
H3N
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O
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H3N
OGATAV
Fig. 13. Synthesis of peptide via multiple ‘click’ centres.Even the short segment of this peptidedY19-K37dwas known to
be a challenging sequence to assemble. Carpino’s attempts to
synthesize Y19-K37 through SPPS via a TentaGel-SRam resin ended
in a very poor yield of 25%. However, when a depsi [(eC]O)eOe]
linkage was introduced at the E27-S28 position, the aggregation
problems were resolved and, after the acyl migration step, the
target peptide was isolated in a decent yield. In this description,
initially, the fragment, TWEKPQELKNH2, was deposited on a Ten-
taGel-SRam resin using standard Fmoc-SPPS. Boc-Ser-OH was
then coupled followed by O-acylation of Ser with Fmoc-Glu(OtBu)-
OH in the presence of N-methylimidazole (NMI). The remaining
amino acids were then assembled as usual. The resulting dep-
sipeptide was cleaved from the resin using triﬂuoroacetic acid
(TFA), and was subjected to OeN acyl migration to restore the
peptide bond (Scheme 57). The product was conﬁrmed through
MALDI-MS (observed value: 2461.12 Da, calculated: 2461.19 Da for
[MþH]þ).H2N
Fmoc/SPPS
TWEKPQELK
Boc-Ser-OH
TWEKPQELKBoc-S
HO
TWEKPQELKBoc-S
-OYYYNNRTLE
TWEKPQELKS
-OYYYNNRTLE
NH2
depsipeptide
N,O-acyl
migration YYYNNRTLESTWEKPQELK-NH2
pH 7.4
TFAFmoc-SPPS
Scheme 57. On-resin preparation of ‘click peptide’ followed by acyl migration in solution.Carpino et al. also investigated the synthesis and use of dep-
sipeptides as units for the automated synthesis of isopeptides.140
This avoids performing O-acylation on resin, which is cumber-
some and racemization prone. Two useful routes were proposed to
synthesize a depsidipeptide, Boc-Thr(Fmoc-Ala)-OH (Scheme 58),
which was employed for an automated synthesis of the 31-mer C-
terminal segment of a globular protein, crambin. During the syn-
thesis of Cram(16e46), the depsipeptide unit was introduced atA27T and was later rearranged to the target sequence. In another
synthesis, the same peptide sequence was assembled by inserting
AT depsipeptide units at two positions (i.e., at 27e28 and 38e39)
and then rearranged to Cram(16e46) (ESI-MS [Mþ2H]2þ¼1570.80;
calculated¼1571.82 Da; Scheme 59).1405.1. O-Acyl isodipeptides
During the assembly of Ac-ValValThrValVal-NH2, Kiso observed
the formation of an undesired isopeptide intermediate epimer,
Thr(Ac-Val-D-Val)ValVal-NH2$TFA (about 21%), along with the de-
sired sequence.141 Racemization at Val was due to the slow esteri-
ﬁcation on solid phase. This led to a new subsidiary approach for
the click peptide protocol, namely ‘O-acyl isodipeptide’ chemistry,
which consists of carrying out the esteriﬁcation of Boc-Ser/Thr with
Fmoc-Xaa-OH in solution and then employing the resulting dep-
sidipeptide unit in the subsequent couplings (Scheme 60).
The O-acyl isodipeptide approach for the racemisation-free
synthesis of O-acyl peptides was a simple alternative, which was
utilized for the synthesis of several peptide sequences including
Ab1e42.142 Kiso’s group, in a thorough study, synthesized all the
possible combinations of O-acyl isodipeptides [Boc-Ser/Thr(Fmoc-
Xaa)OH] to avail them readily as building blocks (Scheme 61).143The enantiomeric purity of these depsipeptide units was estab-
lished ﬂawlessly by synthesizing all the 38 D-isomers [Boc-Ser/
Thr(Fmoc-D-Xaa)OH] and comparing the HPLC data.
5.2. Synthesis of amyloid b-peptide (Ab1e42)
A successful application of the O-acyl isopeptide method was
demonstrated by the preparation of amyloid peptides,144 which
BocNH COOBn
HO H/Me
+ FmocNH COOH
R1 1. coupling
2. catalytic
hydrogenation
BocNH COOH
O H/Me
O
FmocNH
R1
O-acyl isodipeptide unit
Scheme 61. Synthesis of O-acyl isodipeptide units.
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Scheme 59. Synthesis of cram(16e46) demonstrating the utility of the depsidipeptide Boc-Thr(Fmoc-Ala)-OH.
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Scheme 60. Use of O-acyl isodipeptide circumvents the racemisation.
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Scheme 58. Synthesis of depsidipeptide Boc-Thr(Fmoc-Ala)-OH.
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e9537 9527are the components of amyloid plaques found in the brains of
patients with Alzheimer’s disease. Ab1e42 is a predominant
peptide having 42 residues and is also considered as one of the
most difﬁcult peptides to assemble. Its tendency to undergoconcentration and time-dependent aggregation has been a bot-
tleneck to carry out extensive biological studies. This is because,
several properties such as neurotoxicity depend on its b-structure
and, if the peptide undergoes structural deformation before
reaching the target site, the success of the study will be di-
minished. It can, however, be overcome by developing a protocol
to deliver the peptide on to the biological site in a monomeric
form. This was the basis for the synthesis of Ab1e42, which was
accomplished through the O-acyl peptide method. Out of the
entire length of the peptide, the amide bond between Gly25 and
Ser26 was isomerized into an ester bond and the rest of the se-
quence was assembled following standard protocols. After cleav-
age from the resin followed by deprotection of the Boc group
from Ser26, the resulting click peptide O-acyl isoAb1e42 was
easily puriﬁed through HPLC owing to its solubility in aqueous
media (15 mg/ml). The presence of the ester bond between Gly25-
Ser26 in the click peptide blocked the secondary structural prop-
erties completely. The 26-O-acyl isoAb1e42 was stable at 4 C for
about 1 month. In PBS, at pH 7.4, the acyl migration was rapidwith a half-life of 2.6 min and quantitative conversion into the
ﬁnal product Ab1e42 was achieved (22.3 mg; Scheme 62). At pH
4.9, the migration rate was lower with a half-life of 3 h and, at pH
3.5 (acetate buffer), the rearrangement ceased completely.
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val
NH
O
O
H2N
O
10 20
(Gly 25)
(Ser 26)
AsnLysGlyAla
30
IleIleGlyLeuMetValVal GlyGlyValIleAlaHO
H
pH 7.4
PBS
40
A 1-42
click peptide
quant
26-O-acyl isoA 1-42 or
Scheme 62. Synthesis of 42-mer amyloid b-peptide employing O-acyl isopeptide approach.
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e95379528Practical procedures for the solid-phase assembly of difﬁcult pep-
tides by inserting depsilinkages and pseudoproline units have been
reportedbyCoin et al.140 Stepwise procedures, puriﬁcation techniques
and methods to tackle the synthetic difﬁculties have been described,
which adopt direct application of O/N acyl migration or pseudo-
proline-forming reactions for the efﬁcient synthesis of peptides that
otherwise induce unfavourable conformational constraints during
chain assembly.9
The O-acyl isopeptide method has been used for the synthesis,
in complete solution phase, of difﬁcult sequences of few oligo-
peptides such as transmembrane protein fragments.145
5.3. Switch peptides
Borner et al. developed a concept known as ‘switch peptide’
protocol during their studies on peptide guided assembly of poly-
ethylene oxide (PEO)epeptide conjugates.137b The authors’ interest
was in controlling the structure-formation processes in synthetic
polymers mediated by peptides. The designed peptide attached to
the PEO had ﬁve diades of alternating Thr and Val residues [(Thr-
Val)5,], the conventional synthesis of which would complicate the
chemistry due to their instantaneous secondary structure forming
nature. In order to disrupt the aggregating behaviour during the
chemical assembly, acyl linkages were introduced between each
Val-Thr pair. After the synthesis of peptides followed bydetachment
from the solid support, the Boc protections on the switch segments
were removed and allowed for controlled and simultaneous O/N
acyl migrations at pH 6.2 for about 1 week (Scheme 63).PEO
PEO = O 68
HNVal-Gly
O
BocNH
HO
PEOHNVal-Gly
O
H2N
O
ONH
4
H-Gly-Trp-Thr O N-acyl
migration
pH 6.2
Fmoc
Scheme 63. Switch peptide guided assembly of p5.4. Phototriggered O/N acyl migration
Considering the advantages of phototriggered stimulations in
studyingbiological processes of peptides andproteins, photocleavable
protectinggroupswereenvisaged inplaceofBocprotectors forSer/Thr
residues. By ﬁne tuning the area and duration of irradiation, a spatio-
temporal control of the peptide preparation and its functions was
enabled. Kiso’s group employed 6-nitrovertryloxycarbonyl (Nvoc) as
a photocleavable amino-protectinggroup anddemonstrated its utility
for the assembly of Ab1e42. The N-terminus of Ser26was protected as
Nvoc and the rest of the peptide synthesis was carried out under
standard protocols (Scheme 64).146 The protected acyl peptide was
stable, evenafter incubatingat37 C inPBS. Itwasalso stableupto24h
in PBS buffer, and for 3 months either as the solid or as a solution in
DMSO at 20 C. Upon photoirradiation (355 nm, 10 Hz, 5 mJ) for
15 min at 4 C, the Nvoc group detached completely and the O-acyl
peptide was obtained in excellent yield.
A few other photocleavable groups employed in click peptide
chemistry include 4-(dimethylamino)phenyloxycarbonyl (MaPoc),
[7-(diethylamino)coumarin-4-yl]methyloxycarbonyl (DEAC-Moc),
(7-aminocoumarin-4-yl)methyloxycarbonyl (Ac-Moc), and
{7-[bis(carboxymethyl)amino]coumarin-4-yl}methyloxycarbonyl
(BCMAC-Moc).147
Mutter et al. reported the controlled self-assembly of amyloid b-
derived peptides in vitro by consecutive triggering of acyl migra-
tions.148 Sequential triggering of O/N acyl migrations in amyloid
b derived switch peptides has been employed as a tool to un-
derstand the initiation and inhibition of polypeptide folding, self-PEOHNVal-Gly
O
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O
O
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N
H
H
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O OH
O
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Scheme 64. Use of photolabile protecting groups in ‘click peptide’ chemistry.
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e9537 9529assembly and aggregation. A b-amyloid peptide derivative was
prepared initially and the conformational behaviour was tempo-
rarily arrested by inserting switches (Ser/Thr/Cys) at different in-
tervals. The orthogonal Na-protection for each switch ensures
selective triggering of migration at the desired O-acyl junctions,
thereby enabling studying the effect of each segment on the con-
formational behaviour and molecular assembly after undergoing
acyl migration. A representative scheme with two switch positions
and protecting groups along with the corresponding triggering
system is outlined in Fig. 14. When acyl migration at Y1 is executed,
the depsi linkage at Y2 remains intact and the resulting peptide
shows the conformational behaviour due to that particular peptide
segment where the amide bond is newly established. In a similar
way, it is possible to introduce several orthogonal switches at the
desired positions and study the individual contribution of each
segment to the overall aggregation property by selectively trig-
gering the O-acyl migration.Y1HN
O
O H/Me
O
Y2NH
O
H/MeO
O
Protecting group Y
i
:
 H+, Nvoc, ArgPro, pGlu, Arg
Triggering system : OH-, h DPPIV, pGap, Trypsinν,
Fig. 14. A model system comprising two orthogonal switch centres.The click peptide protocol has also been demonstrated for dif-
ﬁcult peptides with cysteine residues. In place of the O-acyl de-
rivative, the S-acyl derivative preserves the monomeric integrity
and, under physiological conditions, the S/N acyl migration re-
stores the amide bond.149 During the synthesis of Ac-ValValCys-
ValVal-NH2, the TFA salt of the S-acyl peptidewas found to be easily
soluble in water (8.5 mg/ml) and therefore was easily puriﬁed
through HPLC in an overall 10% yield. The S-acyl isopeptide was
found to be stable (for 1 day in DMSO ormethanol and for 3monthsFmocHN HNH-Val-Val
Val-Val-NH2
TFA H2N
SAc-Val-Val
O
S N
migrat
PBS, p
25 oC
.
Scheme 65. A click peptide system invowhen stored as a solid at room temperature) and the acyl migration
is quantitative and complete in a very short time (within 1 min;
Scheme 65).6. Recent developments
6.1. KAHA ligation
Bode et al. have developed an alternate and general route for the
reagentless and native peptide bond forming ligation through the
use of a-ketoacid and hydroxylamine (KAHA) bearing peptide
fragments.150 The initial success in this direction was obtained
when the peptide with C-terminal a-keto acid was reacted with the
peptide bearing N-terminal hydroxylamine leading to chemo-
selective ligationwith the formation of an amide bond at the site of
ligation. The main problem of this strategy was the difﬁculty of
performing ligation in aqueous media typically employed for han-
dling medium-sized peptides. This limitation was overcome when
the hydroxylamines were replaced by O-benzyl hydroxylamines,
which provided a clean and rapid ligation in water, but the latter
tend to undergo facile elimination leaving them unsuitable for a-
peptide derived substrates. Later, it was discovered that 5-
oxaproline is a stable and viable alternative to hydroxylamines
for KAHA ligations inwater. The oxaproline reacts chemoselectively
with peptide-a-ketoacids in aqueous medium to afford native
peptide, generating homoserine (HSer) residue at the site of liga-
tion (Scheme 66).150
The utility of this method was demonstrated by synthesizing
two medium-sized proteins from Mycobacterium, the prokaryotic-
ubiquitin-like protein (Pup, 63 residues) and one of its target pro-
teins, probable cold shock protein A (cspA) having 66 residues. For
the preparation of Pup through KAHA ligation, the target peptide
was bisected at Leu32-Thr33 site. The two fragments were made on
an automated SPPS and during the preparation of the C-fragment,
the Thr33 was replaced with (S)-N-Boc-5-oxaproline. The ligations
were performed in DMSO/water (6:4) mixture containing oxalic
acid (0.1 mol) at 60 C for 8 h. The oxalic acid promoted solubili-
zation as well as increased ligation rate. Importantly, in the isolated
protein, it was conﬁrmed through CD spectral studies, that the
replacement of Thr with HSer does not affect the protein secondary
structure. Hence it was envisioned that HSer can serve as surrogateVal-Val
O
BocNH
SFmoc-Val
-acyl
ion
H 7.4,
Ac-Val-Val
H
N
HS
O
Val-Val-NH2
lving S/N acyl migration reaction.
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Scheme 66. Ligation involving KAHA peptides.
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e95379530for Thr, Ser, Met and Asp residues, thus validating the KAHAe
oxaproline ligation as a general method for peptide bond forming
ligations.150Peptide 1 SH
O
CN
Peptide 1 S
O
N
Peptide 1 OBt
O
H2N
R
Peptide 2
O
H
N Peptide 2Peptide 1
O
N
N
N
OH
Scheme 67. Mechanism of acylation of N-terminus of a peptide with a peptide thioacid in presence of an isonitrile component.6.2. Ligation employing peptide thioacids
Danishefsky et al. have developed a general and efﬁcient ligation
protocols for assembling polypeptides and glycopolypeptides by
exploiting the reactivity of thioacids.151 They designed a reaction
involving a peptide thioacid, cyclohexylisonitrile, N-terminal
peptide and HOBt to afford the corresponding ligated peptide.
This strategy was successfully applied to synthesize severalFmoc-RSGDSAGSVGAPRHSWG-COSH
Fmoc-RSGDSAGSVGAPRH
Fmoc-RSGDSAGSVGAPRHSWG-LYTGRLF
H2N-GWPLILG-COSH
DMSO
HOBt,
Fmoc-RSGDSAGSVGAPRHSWG-VPVWAG
FGPELWP (ligation duration 48 h, 80%
other examples:
Fig. 15. HOBt mediatedpolypeptides in 60e82% yield. The reaction proceeds presumably
through a thioformimidate carboxylate mixed anhydride in-
termediate (Scheme 67).Further, the authors conducted a control experiment without
the addition of the isonitrile component and, to their surprise,
found that the reaction worked even better and the respective
peptides were isolated in 77e87% yield in a shorter reaction time
(Fig. 15). The procedure could also be used for the preparation of
cyclic peptides by the use of Na-unprotected peptide thioacids, al-
beit the reaction was found to be slow; and for the synthesis of
glycopeptides as well (Fig. 16).+ H2N-FGPELWP
SWG-FGPELWP
DMSO, A MS
o
HOBt, 12 h
WSAQASLG (ligation duration 12 h; 80%)
, 4A MS
o
GWPLIG
48 h, 81%
)
(ligation duration 20 h; 77%)
82%
4
peptide ligation.
Fig. 16. Structure of EPO. A: amino acid sequence of EPO; B: ribbon diagram with selected oligosaccharides.
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e9537 9531Danishefsky et al. have also demonstrated the reaction of thio-
acid and isonitrile as a possible way to access amides efﬁ-
ciently.30,152 The chemistry was explored to synthesize N-
methylated peptides also (Scheme 68).BocHN SH
O
+ CN OBn
O
1. CHCl3
2. Bu3SnH, AIBN
100 oC, PhMe
BocHN N
O
OBn
O
Scheme 68. Reaction of N-protected amino thioacid with isocyano ester leading to a peptide ester.6.3. NCL at its best: total synthesis of non-glycosylated
erythropoietin
Recently, in 2012, Bralisford and Danishefsky153 and Kent
et al.154 independently accomplished the total synthesis of the non-
glycosylated form of 166-amino acid long protein hormone,
erythropoietin (EPO) using NCL. This marks a landmark achieve-
ment in natural product synthesis especially that of proteins with
tunable structures, and exempliﬁes the present state of art of the
technique as well as the future potential of NCL as a vital synthetic
tool in total synthesis of proteins. The syntheses are built-in with
the wise combination of different strategies and methods de-
veloped thus far for NCL. EPO is a glycosylated protein hormone,
which is secreted by the kidneys and stimulates the production of
blood cells. The hormone is used for the treatment of anaemia. The
glycan units play an important role in the bio-synthesis as well asthe functioning of the hormone. EPO that is produced through
recombinant methods is obtained as heterogeneous mixture of
glycoforms, which differ with respect to glycan residues, thus
complicating the studies on the structureeactivity relationship(SAR) of the hormone. For SAR studies, it is strongly desirable that
a homogeneous sample of EPO is available and that there is a syn-
thetic control over the amount and the content of glycosylation.
The ﬁrst step in addressing this challenge has been taken through
the accomplishment of the total chemical synthesis of the non-
glycosylated form of EPO.
Synthesis of EPO via NCL is challenging as the native Cys resi-
dues (Cys7,29,33,161) are not evenly located. Thus ‘Xaa-Cys’ NCL
cannot be operated with such an uneven distribution of Cys resi-
dues. Bralisford and Danishefsky envisioned the synthesis of EPO
through NCL at the Ala sites of four EPO fragments of comparable
lengths (Scheme 69).153 Non-native Cys residues, which serve as
Ala surrogates were placed at positions 30, 79 and 125 and the EPO
was envisaged to arise from the sequential fusion of four fragments
Ala1-Cys29, Cys30-Gln78, Cys79-Ala124 and Cys125-Arg166 through
three NCL steps. On the other hand, the native Cys residues were
NN
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Scheme 69. Synthesis of non-glycosylated erythropoietin possessing four Acm protected Cys residues.153 A. Synthetic protocol through convergent merger of four peptide frag-
ments via the sequence of NCL. B. ESI-MS of ACM protected EPO: m/z calculated for C827H1336N236O246S5 [Mþ13H]13þ 1437.15, found 1438.62; [Mþ14H]14þ 1334.56, found 1335.70;
[Mþ15H]15þ 1245.66, found 1247.02; [Mþ16H]16þ 1167.87, found 1168.87; [Mþ17H]17þ 1099.23, found 1101.07; [Mþ18H]18þ 1038.22, found 1039.05; [Mþ19H]19þ 983.63, found
984.76; [Mþ20H]20þ 934.50, found 935.23; [Mþ21H]21þ 890.05, found 890.89; [Mþ22H]22þ 849.63, found 850.39; [Mþ23H]23þ 812.74, found 813.53; [Mþ24H]24þ 778.92, found
779.46.
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e95379532protected with Acm groups. Innate to the design of the synthesis,
the N-terminal Cys residues of the middle fragments were pro-
tected as thiazolidine derivatives to circumvent undesired self-
ligation. The required four fragments were assembled following
Fmoc-based SPPS on NovaSyn TGT resin and peptides Ala1-Gly28,Thz30-Gly77 and Thz79-Asp123, after cleavage as acids, were con-
verted into ortho-thiophenolic esters by coupling with the ﬁnal
amino acid bearing thiophenolic ester. These stable thiophenolic
esters were introduced to serve as surrogates for the reactive
arylthioesters. The C-terminus thio-activations of the peptides
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e9537 9533were achieved prior to the commencement of NCL by the reduction
of the disulﬁde bond of the phenolic ester followed by O/S acyl
migration. The Thz residues at the site of ligation were unmasked
into Cys in a sequential manner by hydrolysis with methoxyamine
hydrochloride (MeONH2$HCl) at pH 4.0 before the NCL step. The
four EPO fragments were combined through reiterative NCL and
Thz hydrolysis sequences. The ligations were executed in a phos-
phate buffer of pH 7.2e7.4. The products of ligations were puriﬁed
through HPLC as well as size exclusion centrifugal ﬁltration (in case
of fragment Cys30-Arg166, which could not be puriﬁed through
HPLC). Upon the assembly of the full-length protein, the non-native
Cys residues were selectively converted into native Ala residues by
reduction via metal-free desulfurization using water-soluble radi-
cal initiator VA-044. Thus, 1.4 mg (67% yield) of the Acm protected
EPO was obtained, puriﬁed through centrifugal ﬁltration and
characterized through ESI-MS.
Kent et al.154 synthesized the full-length and fully folded
[Lys24,38,83]EPO by the combination of NCLwith KCL (Scheme 70). In
this EPO mutant, the native Asn24,38,83, which are the sites of N-
glycosylation are replaced with Lys residues. The [Lys24,38,83]EPO
produced through recombinant methods has been used for crys-
tallographic studies and shown to retain biological activity. Kent
et al.154 approached the synthesis by the merger of ﬁve EPO frag-
ments viz., Ala1-Cys29, Ala30-Leu67, Ala68-Lys97, Ala98-Ala127 and
Ala128-Asp165 that carry non-native Cys residues (as Ala surrogates)
at the ligation sites. The native Cys residues were protected withScheme 70. Synthesis of human non-glycosylated [lysine24,38,83]EPO.154 A. Synthetic proto
folded, synthetic [Lys24,38,83]EPO. The chromatographic separation was carried out on an a
gradient of 5e65% buffer B in buffer A over 15 min (buffer A¼0.1% TFA in H2O; buffer B¼0.0
(mass observed: 18,277.90.5 Da; calculated 18,278.1 Da).Acm groups. Although there were three middle fragments, which
impose the temporary protection of Cys, only two were protected
as thiazolidine derivative, while the Cys30 of the other fragment
was left unprotected since the C-a-thioalkylester of this fragment
was selectively ligated to Ala1-Cys29 through KCL. In KCL, difference
in reactivity between aryl- and alkylthioesters is exploited to ach-
ieve selectivity in ligation. The larger fragment Cys68-Asp165 was
obtained by sequential NCL and Thz hydrolysis of fragments Thz98-
Ala127 and Cys128-Asp165 and Thz68-Lys97. Ala1-Leu67-a-thio-
alkylester was prepared by performing KCL at pH 6.8 without the
addition of thiol catalyst. The full-length chain was obtained by the
merger of the thioalkylester to Cys68-Asp165 through an NCL step.
This ligation was achieved at pH 6.8 in presence of 4-
mercaptophenylacetic acid (MPAA) catalyst and took 15 h for
completion. In addition, an unusually large amount of Ala1-Leu67-
OH was formed as byproduct due to the hydrolysis of the thioalkyl
ester. It is also noteworthy, that during the ligation of Thz68-Lys97
fragment, the MPAA mediated removal of Dnp protection on His94,
generated a more reactive a-arylthioester, eCOSC6H4CH2COOH
through transthioesteriﬁcation. From the full-length polypeptide,
the non-native Cys residues at the ligation sites were converted to
native Ala through VA-044 mediated metal-free desulfurization.
The resulting Acm protected EPO was puriﬁed through RP-HPLC
and was characterized through ESI-MS (mass observed:
18,566.20.7 Da; calculated 18,566.4 Da, average isotopes). The
four Acm protections were then cleaved by treating with AgOAc incol employing convergent strategy through NCL and KCL. B. Analytical HPLC trace of
nalytical C3 column (Agilent ZORBAX 300SB, 4.6150 mm; l¼214 nm) using a linear
8% TFA in acetonitrile). C. ESI-MS spectrum of mutant EPO obtained by direct infusion
H.P. Hemantha et al. / Tetrahedron 68 (2012) 9491e95379534AcOH/H2O (1:1) followed by 1,4-dithiothreitol (0.2 M). Thus, 1.9 mg
(41%) of pure polypeptide [Ala1-Cys7,29,33,161-Ala30,68,98,128-Asp165]
EPO was obtained (mass observed: 18,282.61.4 Da; calculated
18,282.1 Da, average isotopes). Folding of the fully unprotected EPO
was achieved through a three-step sequential dialysis of the gua-
nidine hydrochloride (6 M) solution.
The use of NCL in the total chemical synthesis of polypeptides
and proteins of varied length, structure (including post-
translationally modiﬁed molecules)155 and activity is fast grow-
ing. The recent examples in this context include the synthesis of
covalent dimer of HIV-1 protease enzyme (one of the targets in the
therapeutic treatment of AIDS, 203 amino acid residues)68 fully
synthetic homogeneous human follicle-stimulating hormone (FSH,
a-subunit of human glycoprotein hormone, 92 residues),156 human
glycosyl-interferon b (166 amino acids, antitumour agent)157 and
K48-linked tetraqbiquitin protein91c and ubiquitinated peptides
(with varying lengths) and its oligomers.158 The increasing number
of successful syntheses of polypeptides using NCL certainly in-
dicates that chemical assembly of transmembrane proteins in-
cluding GPCR is most likely will be achieved in near future.
7. Conclusions
The need for understanding the biology of proteins and pep-
tides has resulted in several techniques that have made possible
the synthesis of large proteins often on a multimilligram scale,
thus fulﬁlling the demands of biochemical research. The quantity
of proteins obtainable through existing protocols is just enough to
identify, characterize and study a couple of properties and there is
a need to increase the quantities. More than a century-old toil in
the area of protein research has resulted in several innovations,
most of these have the potential restricted to the assembly of
small peptides and their oligomers. Nature has engineered the art
of making proteins without the assistance of protection for diverse
functionalities of amino acids. Emulating this has remained
a daunting challenge for the organic chemists. In this regard,
a new prospective is the protecting-group-free synthesis (PGFS),
which is an emerging area in various subsidiaries of organic
synthesis. The strategies that depend on ligation of unprotected
peptide fragments either synthesized chemically or engineered
biologically have been most successful in assembling proteins. NCL
is a robust technique and has achieved a great reputation among
the chemical and biochemical research community. The success of
NCL is attributed to the development of its biosynthetic version,
EPL, which is contributing considerably to the assembly of pro-
teins. The practical utility of protein splicing for recombinant
generation of large protein fragments bearing ligatable termini
has been a huge leap forward in our exercise to unravel nature’s
mysteries. Traceless Staudinger ligation is an emerging protocol
developed for peptide ligation, which is yet to blossom to its full
strength. Similarly, the click (switch) peptide method is a growing
ﬁeld with the potential for assembling difﬁcult peptides through
the incorporation of temporary depsi linkages in the peptide
backbone. All these chemical ligation methods have made possible
the realization of Emil Fischer’s century-old dream of chemical
synthesis of enzymes and proteins in a test tube. These techniques
are contributing to expanding the horizon of our understanding
about the fascinating biomolecules.
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